0001096906-15-001137.txt : 20151110 0001096906-15-001137.hdr.sgml : 20151110 20151106153539 ACCESSION NUMBER: 0001096906-15-001137 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151106 DATE AS OF CHANGE: 20151106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12575 FILM NUMBER: 151207097 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 10-Q 1 utahmedical.htm UTAH MEDICAL PRODUCTS, INC. 10Q 2015-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10‑Q

Quarterly Report Under Section 13 or 15(d) of

The Securities Exchange Act of 1934

For quarter ended: September 30, 2015

Commission File No. 001-12575

UTAH MEDICAL PRODUCTS, INC.

(Exact name of Registrant as specified in its charter)

UTAH	87‑0342734
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

7043 South 300 West

Midvale, Utah 84047

Address of principal executive offices

Registrant's telephone number:

(801) 566‑1200

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and; (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☒

Non-accelerated filer ☐

Smaller reporting company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒No ☐

Indicate the number of shares outstanding of each of the issuer's classes of common stock as of November 5, 2015: 3,750,300.

UTAH MEDICAL PRODUCTS, INC.

INDEX TO FORM 10‑Q

PART I - FINANCIAL INFORMATION			PAGE

	Item 1.	Financial Statements

		Consolidated Condensed Balance Sheets as of September 30, 2015 and December 31, 2014	1

		Consolidated Condensed Statements of Income for the three and nine months ended September 30, 2015 and September 30, 2014	2

		Consolidated Condensed Statements of Cash Flows for the nine months ended September 30, 2015 and September 30, 2014	3

		Notes to Consolidated Condensed Financial Statements	4

	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operatiosns	6

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	15

	Item 4.	Controls and Procedures	15

PART II – OTHER INFORMATION

	Item 1.	Legal Proceedings	16

	Item 1A.	Risk Factors	16

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18

	Item 6.	Exhibits	19

SIGNATURES			19

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
SEPTEMBER 30, 2015 AND DECEMBER 31, 2014
(in thousands)

	(unaudited)			(audited)
ASSETS	SEPTEMBER 30, 2015			DECEMBER 31, 2014
Current assets:
Cash	$	21,622		$	19,274
Investments, available-for-sale		53			58
Accounts & other receivables, net		5,493			4,703
Inventories		4,449			4,872
Other current assets		689			768
Total current assets		32,306			29,675
Property and equipment, net		7,568			8,236
Goodwill		14,904			15,145
Other intangible assets		38,594			39,675
Other intangible assets - accumulated amortization		(13,217	)		(11,655	)
Other intangible assets, net		25,377			28,020
Total assets	$	80,155		$	81,076

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	922		$	929
Accrued expenses		4,819			4,148
Current portion of notes payable		-			3,894
Total current liabilities		5,741			8,971
Notes payable		-			973
Deferred tax liability - intangible assets		5,039			5,581
Deferred income taxes		1,022			995
Total liabilities		11,802			16,520

Stockholders' equity:
Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding		-			-
Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2015, 3,750 shares and December 31, 2014, 3,748 shares		37			37
Accumulated other comprehensive income (loss)		(4,948	)		(3,234	)
Additional paid-in capital		2,639			2,890
Retained earnings		70,625			64,863
Total stockholders' equity		68,353			64,556

Total liabilities and stockholders' equity	$	80,155		$	81,076

see notes to consolidated condensed financial statements

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2015 AND SEPTEMBER 30, 2014
(in thousands, except per share amounts - unaudited)
	THREE MONTHS ENDED						NINE MONTHS ENDED
	SEPTEMBER 30,						SEPTEMBER 30,
	2015			2014			2015			2014
Sales, net	$	9,945		$	10,717		$	30,575		$	31,035

Cost of goods sold		3,866			4,521			12,285			12,440

Gross profit		6,079			6,196			18,290			18,595

Operating expense

Selling, general and administrative		1,969			2,079			6,039			6,336
Research & development		110			115			406			352

Total operating expense		2,079			2,194			6,445			6,688

Operating income		4,000			4,002			11,845			11,907

Other income (expense)		127			(107	)		(126	)		(300	)

Income before provision for income taxes		4,127			3,895			11,719			11,607

Provision for income taxes		1,080			1,073			3,086			3,229

Net income	$	3,047		$	2,822		$	8,633		$	8,378

Earnings per common share (basic)	$	0.81		$	0.75		$	2.30		$	2.24

Earnings per common share (diluted)	$	0.81		$	0.75		$	2.29		$	2.22

Shares outstanding - basic		3,753			3,741			3,753			3,747

Shares outstanding - diluted		3,768			3,764			3,772			3,774
Other comprehensive income (loss):
Foreign currency translation net of taxes of $0 in all periods	$	(1,536	)	$	(2,569	)	$	(1,711	)	$	(1,459	)
Unrealized gain (loss) on investments net of taxes of ($2), $2, ($2) and $0		(4	)		3			(3	)		(0	)
Total comprehensive income	$	1,507		$	256		$	6,919		$	6,919

see notes to consolidated condensed financial statements

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2015 AND SEPTEMBER 30, 2014
(in thousands - unaudited)

	SEPTEMBER 30,
	2015			2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	8,633		$	8,378
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		461			474
Amortization		1,898			2,064
(Gain) loss on investments		-			-
Provision for (recovery of) losses on accounts receivable		(9	)		(26	)
(Gain) loss on disposal of assets		1			4
Deferred income taxes		(359	)		(414	)
Stock-based compensation expense		66			49
Changes in operating assets and liabilities:
Accounts receivable - trade		(791	)		(291	)
Accrued interest and other receivables		(83	)		(50	)
Inventories		151			(99	)
Prepaid expenses and other current assets		76			22
Accounts payable		31			258
Accrued expenses		(180	)		489
Total adjustments		1,262			2,480
Net cash provided by operating activities		9,895			10,858

CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
Property and equipment		(151	)		(953	)
Intangible assets		(55	)		-
Net cash (used in) provided by investing activities		(206	)		(953	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options		298			361
Common stock purchased and retired		(683	)		(1,017	)
Payment of taxes for exchange of stock options		(42	)		-
Tax benefit attributable to exercise of stock options		110			139
Repayments of notes payable		(4,778	)		(3,052	)
Payment of dividends		(1,914	)		(1,874	)
Net cash (used in) provided by financing activities		(7,009	)		(5,443	)

Effect of exchange rate changes on cash		(332	)		(609	)

NET INCREASE IN CASH		2,348			3,853

CASH AT BEGINNING OF PERIOD		19,274			14,395

CASH AT END OF PERIOD	$	21,622		$	18,248

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for income taxes	$	4,030		$	2,492
Cash paid during the period for interest		65			239

see notes to consolidated condensed financial statements

UTAH MEDICAL PRODUCTS, INC.

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(unaudited)

(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10‑K for the year ended December 31, 2014. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

(2) Recent Accounting Standards. In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

(3) Inventories at September 30, 2015 and December 31, 2014 consisted of the following:

	September 30,		December 31,
	2015		2014
Finished goods	$	1,424	$	1,847
Work‑in‑process		1,212		1,103
Raw materials		1,813		1,922
Total	$	4,449	$	4,872

(4) Stock-Based Compensation. At September 30, 2015, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification ("ASC") 718, Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended September 30, 2015 and 2014, the Company recognized $22 and $25, respectively, in stock based compensation cost. In the nine months ended September 30, 2015 and 2014, the Company recognized $66 and $49, respectively, in stock based compensation cost.

(5) Notes Payable. In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. and a $12,934 loan from JP Morgan Chase, London Branch to help finance UTMD's purchase of Femcare. The notes were fully paid off in February 2015.

(6) Warranty Reserve. The Company's published warranty is: "UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price."

UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2014 or September 30, 2015.

(7) Investments. Changes in the unrealized holding gain/loss on investment securities available-for-sale and reported as a separate component of accumulated other comprehensive income are as follows:

	3Q 2015			3Q 2014
Balance, beginning of period	$	10		$	5
Realized loss from securities included in beginning balance		-			-
Gross unrealized holding gains (losses), in equity securities		(6	)		5
Deferred income taxes on unrealized holding (gain)loss		3			(2	)
Balance, end of period	$	7		$	8

(8) Fair Value Measurements. The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets. The following table provides financial assets carried at fair value measured as of September 30, 2015:

				Fair Value Measurements Using
Description	Total Fair Value at 9/30/2015			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3 )
Equities		$	53		$	53		$	0		$	0

(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

General

UTMD manufactures and markets a well-established range of specialty medical devices. The Company's Form 10-K Annual Report for the year ended December 31, 2014 provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. Because of the relatively short span of time, results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole. Currency amounts in the report are in thousands, except per-share amounts or where otherwise noted. Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; and EUR = Euros.

Analysis of Results of Operations

a) Overview

In the first nine months (9M) of 2015, UTMD met its profit objectives despite continued foreign currency exchange (FX) rate headwinds which reduced total consolidated sales by 4%. About one-third of UTMD's sales are invoiced in GBP, EUR or AUD foreign currencies, which were down 12.6% in the aggregate on a transaction weighted-average basis. The average rates from the applicable foreign currency to USD during third quarter (3Q) and 9M 2015 compared to the same periods of 2014 follow:

	3Q 2015		3Q 2014		change			9M 2015	9M 2014	change
GBP		1.547		1.669		(7.3	%)	1.530	1.669		(8.3	%)
EUR		1.121		1.310		(14.4	%)	1.105	1.356		(18.5	%)
AUD		0.723		0.926		(21.9	%)	0.760	0.920		(17.3	%)
Sales Weighted Average:						(12.5	%)				(12.6	%)

Contrary to what happened in 2014, improved domestic sales in 2015 have offset lower international revenues. Profit margins remained strong compared to the previous year, even though the stronger USD also put pressure on profit margins as a result of shared overhead costs of foreign subsidiaries with the U.S. (in USD) and raw materials and finished devices purchased from the U.S. (in USD) by the foreign subsidiaries. UTMD profit margins in 3Q 2015 and 9M 2015 compared to 3Q 2014 and 9M 2014 follow:

	3Q 2015			3Q 2014			9M 2015		9M 2014
Gross Profit Margin (gross profit/ sales):		61.1	%		57.8	%	59.8	%	59.9	%
Operating Income Margin (operating profit/ sales):		40.2	%		37.3	%	38.7	%	38.4	%
EBT Margin (profit before income taxes/ sales):		41.5	%		36.3	%	38.3	%	37.4	%
Net Income Margin (profit after taxes/ sales):		30.6	%		26.3	%	28.2	%	27.0	%

Income statement results in 3Q and 9M 2015 compared to the same periods of 2014 follow:

	3Q 2015		3Q 2014		change			9M 2015	9M 2014		change
Net Sales	$	9,945	$	10,717	(7.2	%)	$	30,575	$	31,035		(1.5	%)
Gross Profit		6,079		6,196	(1.9	%)		18,290		18,595		(1.6	%)
Operating Income		4,000		4,002	-			11,845		11,907		(0.5	%)
Income Before Tax		4,127		3,895	+5.9	%		11,719		11,607		+1.0	%
Net Income		3,047		2,822	+8.0	%		8,633		8,378		+3.0	%
Earnings per Diluted Share		.809		.750	+7.9	%		2.289		2.220		+3.1	%

Total GAAP consolidated sales in 3Q 2015 were $772 lower (7%) than in 3Q 2014, and in 9M 2015 were $460 lower (1%) than in 9M 2014. Using the same FX rates in 2015 as existed during the same periods in 2014 ("constant FX"), 3Q 2015 consolidated sales were $358 lower (3%) than in 3Q 2014, and in 9M 2015 were $826 higher (+3%) than in 9M 2014. Of course, all of the negative FX impact only affected international sales which resulted in an international share of total consolidated sales of 50% in 3Q 2015 compared to 55% in 3Q 2014, and 49% in 9M 2015 compared to 52% in 9M 2014. International sales in 9M 2015 were $1,308 lower (8%) than in 9M 2014, but in constant FX almost the same. International sales in 3Q 2015 were $950 lower (16%) than in 3Q 2014. Constant FX 3Q 2015 international sales were $535 lower (9%) compared to 3Q 2014. The lower 3Q 2015 constant FX sales were due to a fluctuation in international distributor order patterns. Domestic sales in 3Q 2015 were $178 higher (+4%) compared to 3Q 2014. Domestic sales in 9M 2015 were $848 higher (+6%) compared to 9M 2014.

The higher 3Q 2015 Gross Profit Margin (GPM) was the combined result of a more favorable product mix, as 3Q 2015 sales of low margin blood pressure monitoring (BPM) kits to international distributors were $447 lower than in 3Q 2014, and distribution mix, as domestic sales to end users were higher while international sales to distributors at wholesale prices were lower. For 9M 2015 compared to 9M 2014, better absorption of manufacturing overheads in Utah and Ireland due to higher production activity offset the negative FX impacts on gross profits in Ireland, the UK and Australia.

UTMD's higher operating income margins (OPMs) in 2015 resulted from the FX-induced lower foreign subsidiary operating expenses combined with, in the case of 3Q 2015, a significantly higher GPM. The combination of higher OPMs with lower sales yielded Operating Income in both 3Q 2015 and 9M 2015 about the same as in the same periods in 2014.

With Operating Income about the same, Income Before Tax (EBT) in both 3Q 2015 and 9M 2015 improved compared to the same periods in 2014 as a result of changes in non-operating expense/ income. The changes compared to the prior year were comprised of the elimination of interest expense, a gain in remeasured foreign currency bank balances instead of a loss, and a net increase in income from miscellaneous items including royalties, interest earned and rent from underutilized property, less bank fees.

Net Income increased 8% in 3Q 2015 and 3% in 9M 2015 compared to the same periods in 2014 as a result of the higher EBT combined with lower income tax provision rates. The consolidated average income tax provision rate was 26.2% of EBT in 3Q 2015 compared to 27.6% in 3Q 2014, and 26.3% in 9M 2015 compared to 27.8% in 9M 2014. As of April 1, 2015, the UK corporate income tax rate was reduced to 20% from 21%. A shift of EBT proportion toward Ireland, the lowest tax rate sovereignty, accounted for the remainder of the one and half percentage point reduction in consolidated income tax provision rate.

Earnings Per Share (EPS) in 3Q 2015 increased 5.9 cents (8%) compared to 3Q 2014 as a result of the 8% increase in net income, despite 7% lower revenues. For 9M 2015, EPS increased 6.9 cents (3%) compared to 9M 2014 due to the 3% increase in net income. Diluted shares used to calculate EPS were 3,768,100 in 3Q 2015 compared to 3,764,000 in 3Q 2014. Diluted shares were 3,771,900 in 9M 2015 compared to 3,774,000 in 9M 2014. The fluctuations in diluted shares outstanding are primarily due to the timing and volume of option exercises versus share repurchases.

During 9M 2015, the liquidity of UTMD's Balance Sheet improved. Working Capital increased to $26,565 at September 30, 2015 (Current Ratio 5.6) from $20,704 at December 31, 2014 (Current Ratio 3.3). Total liabilities declined $4,718 and Shareholders' Equity increased $3,797 after paying $1,914 in cash dividends. Total Assets were $921 lower primarily because of the lower FX rates for foreign subsidiary assets, but also because depreciation of fixed assets exceeded capital expenditures for new equipment by $310. UTMD's FX rates for balance sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 9M 2015 and the end of 2014 follow:

	Sep 30, 2015		Dec 31, 2014		change
GBP		1.511		1.559		(3.0	%)
EUR		1.116		1.211		(7.8	%)
AUD		0.702		0.818		(14.2	%)

In addition to the FX impact on foreign subsidiary assets and liabilities, the changes in UTMD's Balance Sheet at September 30, 2015 from December 31, 2014 resulted from continued excellent cash generation, allowing eliminating the remaining principal balances of loans obtained in 2011 to help finance the Femcare acquisition.

b) Revenues

The Company believes that revenue should be recognized at the time of shipment as title generally passes to the customer at the time of shipment, or completion of services performed under contract. Revenue recognized by UTMD is based upon documented arrangements and fixed contracts in which the selling price is fixed prior to acceptance and completion of an order. Revenue from product or service sales is generally recognized at the time the product is shipped or service completed and invoiced, and collectibility is reasonably assured. There are no post-shipment obligations which have been or are expected to be material to financial results.

There are circumstances under which revenue may be recognized when product is not shipped, which meet the criteria of SAB 104: the Company provides engineering services, for example, design and production of manufacturing tooling that may be used in subsequent UTMD manufacturing of custom components for other companies. This revenue is recognized when UTMD's service has been completed according to a fixed contractual agreement.

Terms of sale are established in advance of UTMD's acceptance of customer orders. In the U.S., Ireland, UK and Australia, UTMD generally accepts orders directly from and ships directly to end user clinical facilities, as well as third party med/surg distributors, under UTMD's Standard Terms and Conditions (T&C) of Sale. About 14% of UTMD's domestic end user sales go through third party med/surg distributors which contract separately with U.S. clinical facilities to provide purchasing, storage and scheduled delivery functions for the applicable facility. UTMD's T&C of Sale are substantially the same in the U.S., Ireland, UK and Australia.

UTMD may have separate discounted pricing agreements with a clinical facility or group of affiliated facilities based on volume of purchases. Pricing agreements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes determine the fixed price by part number for the next agreement period of one or two years. For new customers, the customer's best estimate of volume is accepted by UTMD for determining the ensuing fixed prices for the agreement period. New customers typically have one-year agreements. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD's disclosure above that the selling price is fixed prior to the acceptance of a specific customer order.

Total GAAP consolidated sales in 3Q 2015 were $772 lower than in 3Q 2014, and $460 lower in 9M 2015 than in 9M 2014. The negative impact of FX changes on consolidated sales in 3Q 2015 was $414, and in 9M 2015 was $1,286. In other words, non-GAAP constant FX consolidated sales were down 3% in 3Q 2015 compared to 3Q 2014, and up 3% in 9M 2015 compared to 9M 2014.

An easy way to think about the FX impact on consolidated UTMD sales follows: About one-third of UTMD sales are in currencies other than the USD (two-thirds of international sales). If the USD is 12% stronger for the applicable period(s) as a weighted average for all foreign currencies combined, then the impact is about a 4% decrease in consolidated USD GAAP sales (one-third of 12%). This is essentially what happened both in 3Q 2015 and in 9M 2015.

U.S. domestic sales (obviously in constant USD currency) were 4% higher in 3Q 2015 compared to 3Q 2014, and 6% higher in 9M 2015 than in 9M 2014. Sales of Femcare's Filshie Clip System devices to CooperSurgical Inc. (CSI) for distribution in the U.S. were 11% higher in 3Q 2015 compared to 3Q 2014, and 13% higher in 9M 2015 than in 9M 2014. Filshie Clip System sales to CSI were 16% of total domestic sales in 3Q 2015 compared to 15% in 3Q 2014, and 23% in 9M 2015 compared to 21% in 9M 2014. Direct sales of UTMD devices to medical facilities were 1% higher in 3Q 2015 compared to 3Q 2014, and 2% higher in 9M 2015 compared to 9M 2014. U.S. domestic OEM sales were 11% higher in 3Q 2015 compared to 3Q 2014, and 15% higher in 9M 2015 compared to 9M 2014.

International GAAP sales were 16% lower in 3Q 2015 than in 3Q 2014. Constant currency international sales were 9% lower in 3Q 2015 than in 3Q 2014. The lower 3Q sales were due both to the unfavorable FX rates noted above and to less favorable 3Q 2015 economic conditions internationally, including an uneven order pattern of two large distributors of BPM kits, which combined for $349 lower purchases in constant currency terms. International GAAP sales were 8% lower in 9M 2015 than in 9M 2014, but they were the same in constant currency in 9M 2015 and 9M 2014.

Trade sales by UTMD's UK subsidiary, Femcare-Nikomed Ltd, were 28% of total international sales in 3Q 2015 compared to 42% in 3Q 2014, and 30% in 9M 2015 compared to 44% in 9M 2014. Trade sales of Sterishot kits to international customers outside the UK which were included in UK subsidiary sales in 9M 2014 were shipped directly from UTMD's Ireland subsidiary in 9M 2015. In addition, intercompany sales of Sterishot kits to UTMD's Australia distribution subsidiary which were included in 9M 2014 UK sales were shipped directly from UTMD Ireland in 9M 2015. Total UK subsidiary sales were GBP 1,447 in 3Q 2015 compared to GBP 2,159 in 3Q 2014, and GBP 5,314 in 9M 2015 compared to GBP 6,870 in 9M 2014.

Ireland subsidiary trade sales were 30% of total international sales in 3Q 2015 compared to 22% in 3Q 2014, and 28% in 9M 2015 compared to 17% in 9M 2014. The transfer of Sterishot manufacturing to Ireland increased Ireland's share of international sales as it decreased UK's share. Ireland shipments, including trade sales to international third parties as well as intercompany sales, were EUR 1,487 in 3Q 2015 compared to EUR 1,122 in 3Q 2014, and EUR 4,757 in 9M 2015 compared to EUR 2,264 in 9M 2014.

Sales by UTMD's Australia subsidiary, Femcare Australia Pty Ltd, were 13% of total international sales in 3Q 2015 compared to 14% in 3Q 2014, and 13% in 9M 2015 compared to 15% in 9M 2014. All sales by the Australia subsidiary are domestic trade sales to end user facilities in Australia. In 3Q 2015, Australia subsidiary sales were AUD 898 compared to AUD 928 in 3Q 2014, and AUD 2,534 in 9M 2015 compared to AUD 2,605 in 9M 2014.

International trade sales exported from the U.S. invoiced in USD were 29% of total international sales in 3Q 2015 compared to 21% in 3Q 2014, and 29% in 9M 2015 compared to 24% in 9M 2014. Total U.S. international sales including intercompany sales were $1,579 in 3Q 2015 compared to $1,382 in 3Q 2014, and $4,847 in 9M 2015 compared to $4,309 in 9M 2014.

For global GAAP sales (not constant FX) in general product categories, 3Q 2015 blood pressure monitoring device/ components (BPM) sales were down 15%, neonatal device sales were the same, gynecology/ electrosurgery device sales were down 7% and obstetrics device sales were down 5% compared to 3Q 2014. For 9M 2015 compared to 9M 2014, BPM sales were up 6%, neonatal device sales were up 9%, gynecology/ electrosurgery device sales were down 6% and obstetrics device sales were down 1%.

The following table provides USD denominated sales divided into general product categories for total sales, and the subset of international sales:

Global GAAP revenues by product category:

	3Q 2015		3Q 2014			9M 2015		9M 2014
Obstetrics	$	1,147	$	1,205	$	3,455	$	3,508
Gynecology/ Electrosurgery/ Urology		5,558		5,978		17,269		18,381
Neonatal		1,584		1,582		4,798		4,392
Blood Pressure Monitoring and Accessories*		1,656		1,952		5,053		4,754
Total:	$	9,945	$	10,717	$	30,575	$	31,035

International revenues by product category:

	3Q 2015		3Q 2014			9M 2015		9M 2014
Obstetrics	$	147	$	164	$	528	$	488
Gynecology/ Electrosurgery/ Urology		3,564		4,188		10,301		12,036
Neonatal		471		376		1,492		1,081
Blood Pressure Monitoring and Accessories*		796		1,200		2,634		2,658
Total:	$	4,978	$	5,928	$	14,955	$	16,263

*includes molded components sold to OEM customers.

c) Gross Profit

Gross Profit (GP) results from subtracting the cost of manufacturing products (direct materials, direct labor and manufacturing overhead), or the purchase price of finished products which are resold, from revenues. At UTMD, manufacturing overhead costs fully absorb indirect costs including depreciation on manufacturing equipment and facilities, quality assurance, materials requirements planning and purchasing, manufacturing engineering, production supervision, shipping, royalties paid to other entities and health plan benefits for both direct and indirect manufacturing personnel. UTMD's GP margin (GPM) is GP as a percentage of revenues. In 3Q 2015, GP was $6,079 (61.1% GPM) compared to $6,196 (57.8% GPM) in 3Q 2014. In 9M 2015, GP was $18,290 (59.8% GPM) compared to $18,595 (59.9% GPM) in 9M 2014. The higher GPM in 3Q 2015 was the combined result of a more favorable product mix, as 3Q 2015 sales of low margin blood pressure monitoring (BPM) kits to international distributors were $441 lower than in 3Q 2014, and distribution mix, as domestic sales to end users were higher while international sales to distributors at wholesale prices were lower. UTMD Ltd (Ireland subsidiary) had a full quarter of manufacturing and directly shipping Filshie Sterishot kits to international users, in addition to intercompany sales to UTMD's UK and Australia subsidiaries, compared to 3Q 2014 when the Ireland in-house manufacturing of Sterishot had just begun. In the U.S., self-insured employee health plan costs were $95 lower than in 3Q 2014. This one-time savings equates to one full percentage point in the 3Q 2015 consolidated GPM. For 9M 2015 compared to 9M 2014, better absorption of manufacturing overheads in Utah and Ireland due to higher production activity almost offset the negative FX impact on GP in Ireland, the UK and Australia.

d) Operating Income

Operating Income (OP) is the profit remaining after subtracting operating expenses from GP. Operating expenses include sales and marketing (S&M) expenses, product development (R&D) expenses and general and administrative (G&A) expenses. UTMD's OP margin (OPM) is its operating income divided by revenues. OP in 3Q 2015 was $4,000 (40.2% OPM) compared to $4,002 (37.3% OPM) in 3Q 2014, and $11,845 (38.7% OPM) in 9M 2015 compared to $11,907 (38.4% OPM) in 9M 2014. Compared to the prior year's same periods, even though GP were $117 and $304 lower in 3Q 2015 and 9M 2015 respectively, because operating expenses were $115 and $242 lower in 3Q 2015 and 9M 2015, OP were about the same, just $2 and $62 lower in 3Q 2015 and 9M 2015 compared to 3Q 2014 and 9M 2014, respectively.

Consolidated 3Q 2015 operating expenses were $2,079 (20.9% of sales) compared to $2,194 (20.5% of sales) in 3Q 2014. Operating expenses in 9M 2015 were $6,445 (21.1% of sales) compared to $6,688 (21.5% of sales) in 9M 2014. When consolidating foreign subsidiary operating expenses, the lower 2015 FX rates were helpful. In constant FX, 3Q 2015 and 9M 2015 operating expenses of UTMD foreign subsidiaries in the aggregate would have been $103 and $346 higher, respectively.

Consolidated S&M expenses in 3Q 2015 were $533 (5.4% of sales) compared to $524 (4.9% of sales) in 3Q 2014. Consolidated S&M expenses in 9M 2015 were $1,658 (5.4% of sales) compared to $1,674 (5.4% of sales) in 9M 2014. S&M expenses in 3Q 2015 included $74 in U.S. Medical Device Excise Tax (MDET) compared to $73 in 3Q 2014. The MDET was $212 in 9M 2015 compared to $209 in 9M 2014. The MDET, imposed as a component of the Patient Protection and Affordable Care Act (Obamacare), is levied as a 2.3% excise tax on domestic sales of medical devices.

S&M expenses include all customer support costs including training. In general, training is not required for UTMD's devices since they are well-established and have been clinically widely used. Written "Instructions For Use" are packaged with all finished devices. Although UTMD does not have any explicit contracts with customers to provide training, it does have agreements in the U.S. and UK under which it agrees to provide hospital members inservice and clinical training as required and reasonably requested.

UTMD promises prospective customers that it will provide, at no charge in reasonable quantities, copies of instruction materials developed for the use of its devices. UTMD provides customer support from offices in the U.S., UK, Ireland and Australia by telephone, and employed representatives on a geographically dispersed basis, to answer user questions and help troubleshoot any user issues. Occasionally, on a case-by-case basis, UTMD may utilize the services of an independent practitioner to provide educational assistance to clinicians. All inservice and training expenses are routinely expensed as they occur. All of these services are allocated from S&M overhead costs included in Operating Expenses. Historically, marginal consulting costs have been immaterial to financial results.

R&D expenses were $110 (1.1% of sales) in 3Q 2015 compared to $114 (1.1% of sales) in 3Q 2014, and $406 (1.3% of sales) in 9M 2015 compared to $352 (1.1% of sales) in 9M 2014.

Consolidated G&A expenses in 3Q 2015 were $1,436 (14.4% of sales) compared to $1,555 (14.5% of sales) in 3Q 2014, and $4,381 (14.3% of sales) in 9M 2015 compared to $4,661 (15.0% of sales) in 9M 2014. The G&A expenses in 3Q 2015 included $625 (6.3% of sales) of non-cash expense from the amortization of identifiable intangible assets (IIA) resulting from the Femcare acquisition in 2011, which were $674 (6.3% of sales) in 3Q 2014. The $49 difference was due to FX rate conversion into USD since the GBP 404 IIA amortization expense was the same in both periods. IIA amortization expense for 9M 2015 and 9M 2014 were $1,854 (6.1% of sales) and $2,021 (6.5% of sales), respectively, with the difference in USD again being due to FX rate differences.

G&A expenses also include the cost of outside financial auditors and corporate governance activities related to the implementation of SEC rules resulting from the Sarbanes-Oxley and Dodd-Frank Acts, as well as estimated stock-based compensation cost, a noncash expense. Option compensation expense included in G&A expenses was $22 in 3Q 2015 compared to $25 in 3Q 2014, and $66 in 9M 2015 compared to $49 in 9M 2014.

Operating expense summary:

	3Q 2015		3Q 2014			9M 2015		9M 2014
S&M Expense	$	533	$	524	$	1,658	$	1,674
R&D Expense		110		115		406		352
G&A Expense		1,436		1,555		4,382		4,662
Total Operating Expenses:	$	2,079	$	2,194	$	6,446	$	6,688

e) Non-operating expense (NOE)/ Non-operating income (NOI)

Net NOE includes 1) loan interest, 2) bank fees and 3) FX loss from remeasuring the USD value of EUR cash bank balances in the UK and GBP cash balances in Ireland, minus non-operating income from 1) rent of underutilized property, 2) investment income and 3) royalties received from licensing the Company's technology. Net NOI is the converse of the above. In 3Q 2015, net NOI was $127 compared to net NOE of $107 in 3Q 2014. The $234 lower net NOE between 3Q 2015 and 3Q 2014 was due to 1) a $91 gain in remeasured foreign currency bank balances compared to a $66 loss in 3Q 2014, both primarily on EUR held in the UK; 2) the lack of any interest on debt in 3Q 2015, which was $68 in 3Q 2014; and 3) $9 higher royalties et al. In 9M 2015, net NOE was $126 compared to $300 in 9M 2014. The $174 lower net NOE in 9M 2015 was essentially due to $65 in interest expense in 9M 2015 compared to $234 in 9M 2014.

f) Income Before Tax (EBT)

EBT results from subtracting net NOE from OP. Consolidated EBT in 3Q 2015 was $4,127 (41.5% of sales) compared to $3,895 (36.3% of sales) in 3Q 2014. The 5.9% higher EBT in 3Q 2015 resulted from OP about the same (despite 7.2% lower revenue), together with the substantially lower net NOE (higher net NOI). Consolidated EBT in 9M 2015 was $11,719 (38.3% of sales) compared to $11,607 (37.4% of sales) in 9M 2014. The 1.0% higher 9M 2015 EBT resulted from $174 lower net NOE offset by $63 lower operating income compared to 9M 2014.

The EBT of UTMD Ltd. (Ireland) was EUR 1,843 in 9M 2015 compared to EUR 452 in 9M 2014. The EBT of Femcare Group Ltd (Femcare-Nikomed, Ltd., UK and Femcare Australia) was GBP 2,456 in 9M 2015 compared to GBP 3,299 in 9M 2014. The differences were due primarily to the fact that in 2014, Filshie Sterishot kits were purchased from third party subcontract manufacturers and shipped from Femcare-Nikomed in the UK to international customers, while in 2015 the kits are being manufactured by UTMD in-house in Ireland and shipped and invoiced to international customers directly from UTMD Ltd in Ireland.

Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 3Q 2015 consolidated EBT excluding the remeasured bank balance currency translation loss and interest expense ("Non-GAAP adjusted consolidated EBITDA") were $4,857 compared to $4,906 in 3Q 2014. Non-GAAP adjusted consolidated EBITDA in 9M 2015 were $14,348 compared to $14,565 in 9M 2014.

g) Net Income (NP)

NP is EBT minus consolidated provisions for income taxes in the applicable sovereignties. The higher 2015 EBT in both 3Q and 9M periods were leveraged by a lower consolidated tax rate. NP in 3Q 2015 was $3,047 (+8.0%) compared to $2,822 in 3Q 2014. NP in 9M 2015 was $8,633 (+3.0%) compared to $8,378 in 9M 2014. The average consolidated income tax provision (as a % of EBT) in 3Q 2015 was 26.2% compared to 27.6% in 3Q 2014, and in 9M 2015 was 26.3% compared to 27.8% in 9M 2014.

The approximate one and one-half percentage point lower tax provision rate in both 2015 periods of time resulted from a reduced corporate income tax rate in the UK together with a redistribution of EBT toward UTMD Ltd (Ireland), taxed at the lowest rate of all sovereignties.

UTMD's combined state and federal income tax provision rate in the U.S. after all allowable deductions was 34.0% in 9M 2015 compared to 34.3% in 9M 2014. The average corporate income tax provision rate in the UK was 19.9% in 9M 2015 compared to 21.5% in 9M 2014. The average income tax provision rate in Australia was 28.1% in 9M 2015 compared to 30.0% in 9M 2014. The average UTMD Ltd (Ireland) tax provision rate was 12.1% in 9M 2015 compared to 14.6% in 9M 2014. A number of factors, such as the mix of EBT from subsidiaries with differing income tax rates, the amount of non-GAAP taxable EBT in each foreign subsidiary and the amount of U.S. deductions such as the R&D tax credit, result in period to period tax provision fluctuations. UTMD's income tax provision is trued-up each quarter for cumulative year-to-date estimated income tax liability.

NP divided by revenues is UTMD's Net Income margin (NPM). UTMD's respective NPMs were 30.6% in 3Q 2015 compared to 26.3% in 3Q 2014, and 28.2% in 9M 2015 compared to 27.0% in 9M 2014.

h) Earnings Per Share (EPS)

EPS are consolidated NP divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are "in the money," i.e. have exercise prices below the applicable period's weighted average stock market value). Diluted 3Q 2015 EPS were $0.809 (+7.9%) compared to $0.750 in 3Q 2014, and $2.289 (+3.1%) in 9M 2015 compared to $2.220 in 9M 2014. EPS for the most recent twelve months were $3.08.

The weighted average number of diluted shares outstanding used to calculate 3Q 2015 EPS were 3,768,148 compared to 3,763,972 in 3Q 2014. The number of shares added as a dilution factor in 3Q 2015 was 14,649 compared to 22,564 in 3Q 2014. Increases and decreases in UTMD's stock market price impact EPS as a result of the dilution calculation for unexercised options with exercise prices below the average stock market value during each period. Diluted shares outstanding used to calculate 9M 2015 EPS were 3,771,926 compared to 3,774,024 in 9M 2014. The number of shares added as a dilution factor in 9M 2015 was 19,020 compared to 26,980 in 9M 2014.

Actual outstanding shares at the end of 3Q 2015 were 3,749,655 which included 3Q 2015 employee and outside director option exercises of 1,431 shares. The number of shares used for calculating earnings per share was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. The total number of outstanding unexercised employee and outside director options at September 30, 2015 was 64,220 shares at an average exercise price of $38.60/ share, including shares awarded but not vested. This compares to 100,500 unexercised option shares outstanding at September 30, 2014 at an average exercise price of $35.94/ share. No option shares have been awarded to date in 2015.

UTMD repurchased 9,000 of its shares in the open market during 3Q 2015 at an average cost, including commissions and fees, of $51.96 per share ($468 total). The total shares repurchased in 9M 2015 were 13,000 at an average cost of $52.54 per share ($683 total). The Company repurchased 4,083 shares in 3Q 2014 at an average cost of $48.70 per share ($199 total), and 21,427 shares in 9M 2014 at an average cost of $47.47 ($1,017 total). UTMD retains its program for repurchasing shares when they seem undervalued.

i) Return on Equity (ROE)

ROE is the NP retained by UTMD to internally finance its growth, divided by the average accumulated shareholders' equity for the applicable time period. Annualized ROE in 9M 2015 (before payment of dividends to shareholders) was 17% compared to 18% in 9M 2014. The lower ROE in 9M 2015 in spite of higher NP was due to 6.5% growth in average 9M 2015 shareholders' equity compared to 9M 2014. Targeting ROE over 20% remains a key financial objective for UTMD management. ROE can be increased by effectively deploying capital to increase NP, by reducing shareholders' equity from paying cash dividends to shareholders or by repurchasing shares.

Liquidity and Capital Resources

j) Cash flows

Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $9,895 in 9M 2015 compared to $10,858 in 9M 2014. The most significant changes in the two periods were a $669 use of cash for lower accrued expenses and a $500 use of cash for a higher increase in trade accounts receivable. There was also a $255 benefit to cash from higher net income in 9M 2015 compared to 9M 2014.

The Company's reduction of its bank loan principal balances was the most significant use of cash in both years. UTMD repaid the remaining $4,778 principal balance as of December 31, 2014 in 1Q 2015, compared to $3,052 loan principal repaid during 9M 2014. UTMD made cash dividend payments to shareholders of $1,914 in 9M 2015 compared to $1,874 in 9M 2014, a 2% increase.

Capital expenditures for plant, property and equipment (PP&E) were $151 in 9M 2015 compared to $953 in 9M 2014. In the first half of 2014, UTMD invested $550 in completing its new distribution facility in Castle Hill NSW Australia. Depreciation of PP&E was $461 in 9M 2015 compared to $474 in 9M 2014. Except for the possibility of a facility purchase in the UK or an acquisition, planned capital expenditures during the remainder of 2015 are expected to remain less than depreciation of PP&E. The Company continues to keep its facilities, equipment and tooling in good working order.

During 9M 2015, UTMD received a net of $298 and issued 14,256 shares of its stock upon the exercise of employee and director stock options. The shares issued were net of 5,794 shares retired upon optionees trading those shares in payment of the stock option exercise price and related taxes. Option exercises in 9M 2015 were at an average price of $38.60 per share. In comparison, in 9M 2014, the Company received $361 from issuing 20,531 shares of stock on the exercise of employee and director stock options, net of 5,907 shares retired upon optionees trading shares in payment of the stock option exercise price.

UTMD repurchased and retired 13,000 of its own shares during 9M 2015 at a cost of $683, compared to 21,427 shares repurchased in 9M 2014 at a cost of $1,017.

Management believes that income from operations and effective management of working capital will provide the liquidity necessary to finance its internal growth plans. In addition, the Company may use cash for marketing or product manufacturing rights to broaden the Company's product offerings; for continued share repurchases when the price of the stock is undervalued; for cash dividends to stockholders; and if available for a reasonable price, an acquisition that might strategically fit UTMD's business and be accretive to financial performance.

k) Assets and Liabilities

September 30, 2015 total consolidated assets were $921 lower than at December 31, 2014. The decrease was due to a $2,884 decrease in identifiable intangible assets (IIA) from amortization together with a weaker GBP converting the remaining UK IIA asset balance into USD. Other changes were a $790 increase in accounts and other receivables, $668 lower net PP&E book value from $310 in depreciation less new purchases, and a weaker EUR and AUD in UTMD Ltd (Ireland) and Femcare (Australia) where UTMD owns facilities. The accounts and other receivables balances remain well within management's aging targets. Consolidated inventories declined $423, getting back to management's targets after hedging for the start-up of manufacturing Sterishot II in Ireland. The principal balance of the JPMorgan Chase loans associated with the Femcare acquisition has been zero since February 2015.

Working capital (current assets minus current liabilities) increased 28% to $26,565 at September 30, 2015, compared to $20,704 at December 31, 2014. Current liabilities decreased $3,230 due to elimination of the $3,894 current portion of notes payable as of December 31, 2014. Accrued liabilities increased $671 due to the 3Q 2015 quarterly dividend payment to shareholders accrued but not paid until after September 30, whereas the 4Q 2014 dividend was paid before the end of December 2014. UTMD management believes that its working capital remains sufficient to meet normal operating needs and projected cash dividend payments to shareholders.

At September 30, 2015, net intangible assets including goodwill were 50% of total assets compared to 53% at December 31, 2014.

UTMD eliminated all of its remaining bank debt in February 2015. The principal balance of bank debt at December 31, 2014 was 1) $1,750 to JP Morgan Chase in the U.S., of which $350 was long term debt, and 2) $3,117 (2,000 GBP) to JP Morgan Chase in the U.K., of which $2,494 (1,600 GBP) was long term debt. The deferred tax liability balance for Femcare identifiable intangible assets ($9,084 on the date of the acquisition), was $5,039 at September 30, 2015 compared to $5,581 at December 31, 2014. Reduction of the deferred tax liability occurs as the book/tax difference of IIA amortization is eliminated over the remaining useful life of the IIA. UTMD's total debt ratio (total liabilities/total assets) as of September 30, 2015 declined to 15% from 20% as of December 31, 2014.

l) Management's Outlook.

As outlined in its December 31, 2014 SEC 10-K report, UTMD's plan for 2015 is to

1)	continue to exploit distribution and manufacturing synergies by further integrating capabilities and resources in its multinational operations;
2)	introduce additional products helpful to clinicians through internal new product development;
3)	continue achieving excellent overall financial operating performance;
4)	utilize positive cash generation to eliminate debt remaining from the Femcare acquisition, continue cash dividends to shareholders and continue open market share repurchases if/when the UTMD share price seems undervalued; and
5)	be vigilant for accretive acquisition opportunities which may be increasingly brought about by difficult burdens on small, innovative companies, including especially the MDET.

Despite the much larger than anticipated negative impact of FX rates on 9M 2015 consolidated revenues, operating performance in the first nine months of the 2015 year was on track to meet UTMD's previously stated financial objectives for the year.

m) Accounting Policy Changes.

None.

Forward-Looking Information. This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. When used in this document, the words "anticipate," "believe," "project," "estimate," "expect," "intend" and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP) and in Australia denominated in the Australia Dollar (AUD). The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. The exchange rates were .8958, .8258 and .7922 EUR per USD as of September 30, 2015, December 31, 2014 and September 30, 2014, respectively. Exchange rates were .6616, .6416 and .6165 GBP per USD as of September 30, 2015, December 31, 2014 and September 30, 2014, respectively. Exchange rates were 1.4241, 1.2223 and 1.1452 AUD per USD on September 30, 2015, December 31, 2014 and September 30, 2014, respectively. UTMD manages its foreign currency risk without separate hedging transactions by conducting as much business in local currencies as is practicable, and by optimizing global account structures through liquidity management accounts.

Item 4. Controls and Procedures

The Company's management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of September 30, 2015. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of September 30, 2015, the Company's disclosure controls and procedures were effective.

There were no changes in the Company's internal controls over financial reporting that occurred during the quarter ended September 30, 2015, that have materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company may be a party from time to time in litigation incidental to its business. Presently, there is no litigation.

Item 1A. Risk Factors

In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in UTMD's Annual Report on Form 10-K for the year ended December 31, 2014, which could materially affect its business, financial condition or future results. The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company's business, financial condition and/or operating results.

Legislative healthcare reform in the United States, as embodied in The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (the "Acts") adds a substantial excise tax that began in 2013, increases administrative costs and has led to decreased revenues in the U.S.:

The voluminous Acts, administrative rules to enforce the Acts and promised efforts to reform the Acts, make the U.S. medical device marketplace unpredictable, particularly for the thousands of small medical device manufacturers including UTMD that do not have the overhead structure that the larger medical device companies can afford. To the extent that the Acts continue to place additional burdens on small medical device companies in the form of the excise tax on medical device sales, additional oversight of marketing and sales activities and new reporting requirements, the result is likely to continue to be negative for UTMD's ability to effectively compete and support continued investments in new product development and marketing of specialty devices in the U.S.

Increasing regulatory burdens including premarketing approval delays may result in significant loss of revenue, unpredictable costs and loss of management focus on helping the Company thrive:

The Company's experience in 2001-2005, when the FDA improperly sought to shut it down highlights the ongoing risk of being subject to a regulatory environment which can be arbitrary and capricious. The risks associated with such a circumstance relate not only to the substantial costs of litigation in millions of dollars, but also loss of business, the diversion of attention of key employees for an extended period of time, from new product development and routine quality control management activities, and a tremendous psychological and emotional toll on employees.

Since the FDA reserves to itself the interpretation of which vague industry standards comprise law at any point in time, it is impossible for any medical device manufacturer to ever be confident that it is operating within the Agency's version of the law. The result is that companies, including UTMD, are considered guilty prior to proving their innocence.

New premarketing submission administrative burdens and substantial increases in "user fees" increase product development costs and result in delays to revenues from new or improved devices.

The growth of Group Purchasing Organizations (GPOs) adds non-productive costs, typically weakens the Company's marketing and sales efforts and may result in lower revenues:

GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting their revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD's, into undifferentiated commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. In any other industry, their business model based on "kickbacks" would be a violation of law. These bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily related to collection of their administrative fees.

The Company's business strategy may not be successful in the future:

As the level of complexity and uncertainty in the medical device industry increases, evidenced, for example, by the unpredictable regulatory environment, the Company's views of the future and product/ market strategy may not yield financial results consistent with the past.

As the healthcare industry becomes increasingly bureaucratic it puts smaller companies like UTMD at a competitive disadvantage:

An aging population and an extended economic recession are placing greater burdens on healthcare systems, particularly hospitals. The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years. Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs. As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain clinical users because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products and services. Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD's clinical advantages much more difficult.

A product liability lawsuit could result in significant legal expenses and a large award against the Company:

UTMD's devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case. In any lawsuit where an individual plaintiff suffers permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists.

The Company's reliance on third party distributors in some markets may result in less predictable revenues:

UTMD's distributors have varying expertise in marketing and selling specialty medical devices. They also sell other devices that may result in less focus on the Company's products. In some countries, notably China, Pakistan and India not subject to similarly rigorous standards, by copying, a distributor of UTMD's products may eventually become a competitor with a cheaper but lower quality version of UTMD's devices.

The loss of one or more key employees could negatively affect UTMD performance:

In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance. The Company's benefits programs are key to recruiting and retaining talented employees. The rapid increase in UTMD's employee healthcare plan costs, for example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.

Fluctuations in foreign currencies relative to the U.S. Dollar (USD) can result in significant differences in period to period financial results:

Since a significant portion of UTMD's sales are outside the U.S. and consolidated financial results are reported in USD terms, a stronger USD can have negative effects. For the portion of sales to foreign entities made in fixed USD terms, a stronger USD makes the devices more expensive and weakens demand. For the portion invoiced in a foreign currency, not only USD denominated sales and profits are reduced, but also gross profits and operating profits in foreign currency terms are reduced because finished distributed products and/or U.S. made raw materials and components are being purchased in fixed USD.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table details purchases by UTMD of its own securities during 3Q 2015.

ISSUER PURCHASES OF EQUITY SECURITIES

Period	Total Number of Shares Purchased (1)		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)		Maximum Number (or Approximate Dollar Value) of Shares that May be Purchased Under the Plans or Programs (1)
7/01/15 – 7/31/15		-		-		-
8/01/15 – 8/31/15		9,000	$	51.96		9,000
9/01/15 – 9/30/15		-		-		-
Total		9,000	$	51.96		9,000

(1)

In 3Q 2015 UTMD repurchased the above shares pursuant to a continued open market repurchase program initially announced in August 1992. Since 1993 through 3Q 2015, the Company has repurchased 6.8 million shares at an average cost of $12.72 per share including broker commissions and fees in open market transactions. In addition, the Company conducted tender offer transactions in which it purchased an additional 2.8 million shares at an average cost of $9.76 per share including fees and administrative costs. In total, UTMD has repurchased 9.6 million of its shares at an average price of $11.86 per share since 1993. To complete the picture relating to current shares outstanding, since 1993 the Company's employees and directors have exercised and purchased 1.9 million option shares at an average price of $10.99 per share. All options were awarded at the market value of the stock on the date of the award.

The frequency of UTMD's open market share repurchases depends on the availability of sellers and the price of the stock. The board of directors has not established an expiration date or a maximum dollar or share limit for UTMD's continuing and long term consistent pattern of open market share repurchases.

The purpose of UTMD's ongoing share repurchases is to maximize the value of the Company per share for its continuing shareholders, and maximize its return on shareholder equity by employing excess cash generated by effectively managing its business. Although UTMD has repurchased approximately 70% of its shares that were outstanding 22 years ago, it does not intend to repurchase shares that would result in terminating its Nasdaq Global Market listing.

Item 6. Exhibits

Exhibit #	SEC Reference #	Title of Document

1	31	Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

2	31	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

3	32	Certification of CEO pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

4	32	Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

5	101.ins	XBRL Instance

6	101.sch	XBRL Schema

7	101.cal	XBRL Calculation

8	101.def	XBRL Definition

9	101.lab	XBRL Label

10	101.pre	XBRL Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		UTAH MEDICAL PRODUCTS, INC.
	REGISTRANT

	Date: 11/6/15	By: /s/ Kevin L. Cornwell
		Kevin L. Cornwell
		CEO

	Date: 11/6/15	By: /s/ Paul O. Richins
		Paul O. Richins
		Principal Financial Officer

EX-31.1 2 exhibit311.htm CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 1

CERTIFICATION OF CEO

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin L. Cornwell, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2015

/s/ Kevin L. Cornwell

Kevin L. Cornwell

Chief Executive Officer

EX-31.2 3 exhibit312.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul O. Richins, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2015

/s/ Paul O. Richins

Paul O. Richins

Principal Financial Officer

EX-32.1 4 exhibit321.htm CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. ?1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 3

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Kevin L. Cornwell

Kevin L. Cornwell

Chief Executive Officer

November 6, 2015

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 exhibit322.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. ?1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 4

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Paul O. Richins, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Paul O. Richins

Paul O. Richins

Principal Financial Officer

November 6, 2015

EX-101.INS 6 utmd-20150930.xml XBRL INSTANCE DOCUMENT

53000

58000

5493000

4703000

689000

768000

32306000

29675000

7568000

8236000

14904000

15145000

38594000

39675000

13217000

11655000

25377000

28020000

80155000

81076000

922000

929000

4819000

4148000

3894000

5741000

8971000

973000

5039000

5581000

1022000

995000

11802000

16520000

37000

-4948000

-3234000

2639000

2890000

70625000

64863000

68353000

64556000

80155000

81076000

0.01

5000000

0.01

50000000

3750000

3748000

3750000

3748000

9945000

10717000

30575000

31035000

3866000

4521000

12285000

12440000

6079000

6196000

18290000

18595000

1969000

2079000

6039000

6336000

110000

115000

406000

352000

2079000

2194000

6445000

6688000

4000000

4002000

11845000

11907000

127000

-107000

-126000

-300000

4127000

3895000

11719000

11607000

1080000

1073000

3086000

3229000

3047000

2822000

0.81

0.75

2.30

2.24

0.81

0.75

2.29

2.22

3753000

3741000

3753000

3747000

3768000

3764000

3772000

3774000

-1536000

-2569000

-1711000

-1459000

-4000

3000

-3000

1507000

256000

6919000

-2000

2000

-2000

8633000

8378000

461000

474000

1898000

2064000

-9000

-26000

-1000

-4000

-359000

-414000

66000

49000

791000

291000

83000

50000

-151000

99000

-76000

-22000

31000

258000

-180000

489000

1262000

2480000

9895000

10858000

151000

953000

55000

-206000

-953000

298000

361000

-683000

-1017000

42000 0

110000

139000

4778000

3052000

1914000

1874000

-7009000

-5443000

-332000

-609000

2348000

3853000

19274000

14395000

21622000

18248000

4030000

2492000

65000

239000

(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States.  These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2014.  In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

(2) Recent Accounting Standards. In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted.  UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

(3) Inventories at September 30, 2015 and December 31, 2014 consisted of the following:   <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> September 30, 2015 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> December 31, 2014 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Finished goods </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="144" valign="top" style='width:1.5in;border:none;background:#CCEEFF;padding:0'> 1,424 </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="135" valign="top" style='width:101.0pt;border:none;background:#CCEEFF;padding:0'> 1,847 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> Work-in-process </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;padding:0'> 1,212 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;padding:0'> 1,103 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Raw materials </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> 1,813 </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> 1,922 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> Total </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> $ </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:double windowtext 1.5pt;padding:0'> 4,449 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> $ </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> 4,872 </td> </tr> </table>

(4) Stock-Based Compensation.  At September 30, 2015, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.  The Company accounts for stock compensation under FASB Accounting Standards Codification (ASC) 718, Stock Compensation.  This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.  In the quarters ended September 30, 2015 and 2014, the Company recognized  $22 and $25, respectively, in stock-based compensation cost. In the nine months ended September 30, 2015 and 2014, the Company recognized $66 and $49, respectively, in stock based compensation cost.

(5) Notes Payable.  In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. and a $12,934 loan from JP Morgan Chase, London Branch to help finance UTMDs purchase of Femcare.  The notes were fully paid off in February 2015.

(6) Warranty Reserve.  The Companys published warranty is: UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment.  During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.   UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2014 or September 30, 2015.

(7) Investments.  Changes in the unrealized holding gain/loss on investment securities available-for-sale and reported as a separate component of accumulated other comprehensive income are as follows:   <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="top" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 3Q 2015 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="top" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 3Q 2014 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Balance, beginning of period </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;background:#CCEEFF;padding:0'> 10 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;background:#CCEEFF;padding:0'> 5 </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;padding:0'> Realized loss from securities included in beginning balance </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;padding:0'> ~ </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;padding:0'> ~ </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;background:#CCEEFF;padding:0'> Gross unrealized holding gains (losses), in equity securities </td> <td width="9" valign="top" style='width:6.5pt;background:#CCEEFF;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;background:#CCEEFF;padding:0'> (6) </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;background:#CCEEFF;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;background:#CCEEFF;padding:0'> 5 </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;padding:0'> Deferred income taxes on unrealized holding (gain) loss </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 3 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> (2) </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Balance, end of period </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 7 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'>  8 </td> </tr> </table>

(8) Fair Value Measurements.  The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets.  The following table provides financial assets carried at fair value measured as of September 30, 2015:   <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="96" valign="top" style='width:1.0in;padding:0'>   </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="96" valign="top" style='width:1.0in;padding:0'>   </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td colspan="8" valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Fair Value Measurements Using </td> </tr> <tr align="left"> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Description </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Total Fair Value at 9/30/2015 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>  Quoted Prices in Active Markets for Identical Assets (Level 1) </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>  Significant Other Observable Inputs (Level 2) </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> Significant Unobservable Inputs (Level 3 ) </td> </tr> <tr align="left"> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> Equities </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> 53 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 53 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 0 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 0 </td> </tr> </table>

(9) Subsequent Events.  UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted.  UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

<table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> September 30, 2015 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> December 31, 2014 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Finished goods </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="144" valign="top" style='width:1.5in;border:none;background:#CCEEFF;padding:0'> 1,424 </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="135" valign="top" style='width:101.0pt;border:none;background:#CCEEFF;padding:0'> 1,847 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> Work-in-process </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;padding:0'> 1,212 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;padding:0'> 1,103 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Raw materials </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> 1,813 </td> <td width="11" valign="top" style='width:8.5pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0'> 1,922 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'> Total </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> $ </td> <td width="144" valign="top" style='width:1.5in;border:none;border-bottom:double windowtext 1.5pt;padding:0'> 4,449 </td> <td width="11" valign="top" style='width:8.5pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> $ </td> <td width="135" valign="top" style='width:101.0pt;border:none;border-bottom:double windowtext 1.5pt;padding:0'> 4,872 </td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="192" valign="top" style='width:2.0in;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="top" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 3Q 2015 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="top" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 3Q 2014 </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Balance, beginning of period </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;background:#CCEEFF;padding:0'> 10 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;background:#CCEEFF;padding:0'> 5 </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;padding:0'> Realized loss from securities included in beginning balance </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;padding:0'> ~ </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;padding:0'> ~ </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;background:#CCEEFF;padding:0'> Gross unrealized holding gains (losses), in equity securities </td> <td width="9" valign="top" style='width:6.5pt;background:#CCEEFF;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;background:#CCEEFF;padding:0'> (6) </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;background:#CCEEFF;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;background:#CCEEFF;padding:0'> 5 </td> </tr> <tr align="left"> <td width="192" valign="bottom" style='width:2.0in;padding:0'> Deferred income taxes on unrealized holding (gain) loss </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> 3 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> (2) </td> </tr> <tr align="left"> <td width="192" valign="top" style='width:2.0in;background:#CCEEFF;padding:0'> Balance, end of period </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 7 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> $ </td> <td width="105" valign="bottom" style='width:79.0pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'>  8 </td> </tr> </table>

<table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="96" valign="top" style='width:1.0in;padding:0'>   </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;padding:0'>   </td> <td width="96" valign="top" style='width:1.0in;padding:0'>   </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td colspan="8" valign="top" style='border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Fair Value Measurements Using </td> </tr> <tr align="left"> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Description </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0'> Total Fair Value at 9/30/2015 </td> <td width="12" valign="top" style='width:8.65pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>  Quoted Prices in Active Markets for Identical Assets (Level 1) </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>  Significant Other Observable Inputs (Level 2) </td> <td width="12" valign="top" style='width:8.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'>   </td> <td width="115" valign="bottom" style='width:1.2in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0'> Significant Unobservable Inputs (Level 3 ) </td> </tr> <tr align="left"> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> Equities </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="96" valign="top" style='width:1.0in;border:none;background:#CCEEFF;padding:0'> 53 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 53 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 0 </td> <td width="12" valign="top" style='width:8.65pt;background:#CCEEFF;padding:0'>   </td> <td width="9" valign="top" style='width:6.5pt;border:none;background:#CCEEFF;padding:0'> $ </td> <td width="115" valign="top" style='width:1.2in;border:none;background:#CCEEFF;padding:0'> 0 </td> </tr> </table>

1424000

1847000

1212000

1103000

1813000

1922000

4449000

4872000

22000

25000

66000

49000

14000000

12934000

10000 5000

-6000

5000

3000

-2000

7000 8000

53000

10-Q 2015-09-30 false UTAH MEDICAL PRODUCTS INC 0000706698 utmd --12-31 3750300 199695980 Accelerated Filer Yes No No 2015 Q3 0000706698 2014-06-30 0000706698 2013-12-31 0000706698 2014-01-01 2014-09-30 0000706698 2014-09-30 0000706698 2014-07-01 2014-09-30 0000706698 2015-01-01 2015-09-30 0000706698 2015-06-30 0000706698 2015-09-30 0000706698 2014-12-31 0000706698 2015-07-01 2015-09-30 0000706698 fil:JPMorganChaseBankNAChaseNoteMember 2015-09-30 0000706698 fil:JPMorganChaseLondonBranchNoteMember 2015-09-30 0000706698 us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000706698 us-gaap:FairValueInputsLevel1Member 2015-09-30 0000706698 us-gaap:FairValueInputsLevel2Member 2015-09-30 0000706698 us-gaap:FairValueInputsLevel3Member 2015-09-30 0000706698 2015-11-05 iso4217:USD shares iso4217:USD shares

New Accounting Pronouncements and Changes in Accounting Principles	9 Months Ended
Sep. 30, 2015
Notes
New Accounting Pronouncements and Changes in Accounting Principles	(2) Recent Accounting Standards. In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

EX-101.SCH 7 utmd-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000160 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Investments: Available-for-sale Securities (Details) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Warranty Reserve link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Inventories: Schedule of Inventory, Current (Details) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Investments: Available-for-sale Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Investments link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 utmd-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 utmd-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 utmd-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Fair Value, Measurement Frequency Long-term Debt, Type [Axis] Schedule of Inventory, Current Net cash provided by (used in) financing activities Net cash provided by (used in) financing activities Payment of dividends Payment of dividends Net income Net income Total operating expense Total operating expense Common Stock, Shares Issued Accumulated other comprehensive income (loss) Other intangible assets Total current assets Total current assets Accounts & other receivables - net Document Fiscal Year Focus Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Subsequent Events New Accounting Pronouncements and Changes in Accounting Principles CASH FLOWS FROM FINANCING ACTIVITIES: Capital expenditures for intangible assets Capital expenditures for intangible assets CASH FLOWS FROM INVESTING ACTIVITIES: CASH FLOWS FROM OPERATING ACTIVITIES: Unrealized gain (loss) on investments net of taxes of ($2), $2, ($2) and $0 Other comprehensive income (loss): Income Statement Common Stock, Par Value Per Share TOTAL ASSETS TOTAL ASSETS Goodwill Realized loss from securities included in beginning balance Finished goods Policies Net cash provided by operating activities Net cash provided by operating activities Accrued interest and other receivables Accrued interest and other receivables Income before provision for income taxes Income before provision for income taxes Other income (expense) Cost of goods sold Entity Filer Category Debt Instrument, Face Amount New Accounting Pronouncements, Policy Net increase in cash and cash equivalents Net increase in cash and cash equivalents Accounts payable {1} Accounts payable ASSETS Document Type Deferred income taxes on unrealized holding (gain) loss Statement [Table] Payment of taxes for exchange of stock options Payment of taxes for exchange of stock options This element represents the total of the cash outflow during the period for taxes related to exchanges of stock options. Proceeds from issuance of common stock - options Amortization Adjustments to reconcile net income to net cash provided by operating activities: Earnings per common share (diluted) Gross profit Gross profit Retained earnings Other intangible assets - net Other intangible assets - net Cash {1} Cash Cash at beginning of period Cash at end of period Current assets: Entity Well-known Seasoned Issuer Entity Central Index Key Statement [Line Items] Allocated Share-based Compensation Expense Details Notes Payable {1} Notes Payable Prepaid expenses and other current assets Prepaid expenses and other current assets Entity Common Stock, Shares Outstanding Long-term Debt, Type Cash paid during the period for income taxes Shares outstanding (diluted) Research and development Preferred Stock, Shares Issued Deferred income taxes Total current liabilities Total current liabilities Fair Value, Measurements, Fair Value Hierarchy Measurement Frequency [Axis] Work-in-process Effect of exchange rate changes on cash Accrued expenses {1} Accrued expenses Foreign currency translation tax adjustment Provision for income taxes Additional paid-in capital Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2015, 3,750 shares and December 31, 2014, 3,748 shares Property and equipment - net Inventories Total Entity Registrant Name Available-for-sale Securities, Gross Unrealized Gain (Loss) JP Morgan Chase Bank NA (Chase) Note Provision for (recovery of) losses on accounts receivable Depreciation Shares outstanding (basic) Common Stock, Shares Authorized Statement of Financial Position Document and Entity Information: Repayment of notes payable Repayment of notes payable Common stock purchased and retired Capital expenditures for property and equipment Capital expenditures for property and equipment Operating income Operating income Stockholders' equity: Document Fiscal Period Focus Entity Voluntary Filers Available-for-sale Securities {1} Available-for-sale Securities Fair Value Measurements Total comprehensive income Total comprehensive income Sales, net Preferred Stock, Shares Outstanding Preferred Stock, Shares Authorized Amendment Flag JP Morgan Chase London Branch Note Warranty Reserve Stock-Based Compensation (Gain) loss on investments (Gain) loss on investments Unrealized gain (loss) on investments tax adjustment TOTAL LIABILITIES TOTAL LIABILITIES Current portion of notes payable Accounts payable Current liabilities: LIABILITIES AND STOCKHOLDERS' EQUITY Fair Value, Inputs, Level 2 Fair Value, Hierarchy [Axis] Cash paid during the period for interest Accounts receivable Accounts receivable Stock-based compensation expense (Gain)/Loss on disposal of assets (Gain)/Loss on disposal of assets Common Stock, Shares Outstanding Accrued expenses Other intangible assets - accumulated amortization Other intangible assets - accumulated amortization Investments, available-for-sale Document Period End Date Net cash provided by (used in) investing activities Net cash provided by (used in) investing activities Statement of Cash Flows Selling, general and administrative Entity Public Float Current Fiscal Year End Date Equities Basis of Presentation Foreign currency translation net of taxes of $0 in all periods Total stockholders' equity Total stockholders' equity Entity Current Reporting Status Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 1 Fair Value, Measurements, Recurring Raw materials Tables/Schedules Investments {1} Investments Tax benefit attributable to exercise of stock options Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments Net amount of accumulated unrealized gains (losses) on investments in available-for-sale securities impacting investments. Represents the difference between the fair value and cost of investments in available-for-sale securities. Inventories {2} Inventories Notes Total adjustments Total adjustments Inventories {1} Inventories Changes in operating assets and liabilities: Deferred income taxes {1} Deferred income taxes Earnings per common share (basic) Operating expense: Preferred Stock, Par Value Per Share TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Deferred tax liability - intangible assets Notes payable Other current assets Trading Symbol EX-101.PRE 11 utmd-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`)%\9D?[QI0%D@$``#$1```3````6T-O;G1E;G1?5'EP97-= M+GAM;,U8RT[#,!#\E2I7U+@.4!YJ>Z%W!/B\@HD0&#AST0:T\39HS@.?-<*U*KHE5UJ,N2 MYU#H?"U#2NH#-5P$/!DLF/5/3(829"M(`^R?-(TX.0^A,Q98X2H`+T7J_$Z` MZ^+?(Q_,^39.`NJ,8VHF_*>,R-LVH MY;>,./_C6EJ;6$LQMVS#6P1U;VV*8RH95UVMVFB[>M-Z=+%V]#?[KOQ-:`_';&OS?M/ M36]`1YJA1Y,X24>&1,QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^ M.R6:E((C-Z."N[_8_`)02P,$%`````@`D7QF1[:A'7%.`0``Q0\``!H```!X M;"]?J$.Y6@4A>M&LP%.+-NKMO$8.7\PTVTP;3\F/$_VQOZ[HK\6K+UP%-^*-" M?FT@9#Q(Q8,42]`V'K1E"=K%@W8L0?MXT)XE*(L'92Q!AWC0@27H&`\ZL@2= MXD$GEB!("1E3GB0*:QZM@>`:>+P&`FS@$1L(LH'';"#0!AZU@6`;>-P&`F[@ MD1L(NH'';B#P!AZ]%:&WXM%;$7HKIK,V==CFT5L1>BL>O16AM^+16RWT]JUV M6#T'UYG&KUWS;3A9M,#;AT>/ZZ?,4\F&A=9AV@GE?%W]VYJG?H;(7W_LEP]0 M2P,$%`````@`D7QF1P5]M+-@`@``Q@<``!````!D;V-0&UL MO57=;]HP$/]7K#QMTFAHQOJ`:"06F(K4#U0H?:Q`TH,BST!D5KI-V*TP356)F0FN(*)<8<(50H7ZIRPQD5FG M7&_\ZG0I]1/>I7,SX@Z:7KN&*OJ*6X@IZ4[T6EEB+C;4IRI\HQ772XB;V/?& M+1<+L%AT>AJ<=.FK*=CJJ]C`8ZF74RXMAH/<]7,0SMC7,>7NV"G%1A1#Q\6< MZD.//7*$0CSW!PX-?*4FQBF[+L MA4&O1)"TB_3KSL)7VG;Z+C1SZ13@33+EUOTG*LJ>:B)Z7J/[;0C&=3:'C)IKB<[(: M2SNGU3YS1CQUJ`:(6;$30..!`HRC?3CE&_ZHH!5QSZVEZ[MAM]2+S=M!14WH MRJI;[;_HBK,%5QFP*^"86=B/G66/"+^SXMZ-\[VH@\R=ML^EP=P#F]$#BC,% MQ9PJPT>=/;!ASJ4JF.K0(^@@WT/9GFZW.3]?6]#]U*39EQ$X+C\>^"M0X=?/ M]QZTO\N#O0>]=VNTN0_?;#]_]Z\=_@502P,$%`````@`D7QF1V]1A7T^`0`` M:0,``!$```!D;V-0R,;4U%1GU=1<<-#[BT M4JT5R-MN+/N=BIT1O`XG.4(5E?>0AJJ&K;=M*6J2X.3,G;\O$Y MG4VN3$!N!$154`P[!XOLW/FUO+M?/63UM*"SG-*\F*_HC)5S5M+WXV07_D;# MNA_BWSH^&TS;184-7+G;I)%IN>DS@20$X95#9621A'^_1S80RY8-[9)-NIL\!"SI M^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3& MK!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.7 M6!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5 M,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z>`HW MEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN M,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3 MET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1 ML*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@ M+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(Y MPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q; MB%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R< M><41`71%`B.5'`86%S+D4.Z2D`83``>LX=SFWJX MPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2"; M_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F`6/,, MH68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\- ML,+$CN'MB[\!4$L#!!0````(`)%\9D>EA@7^.`(``.<(```-````>&POG'L.!#29=.D?Y]5G M!]2AH?:&&I*H$'Q>B@&2J'D!6T2U?V#<,T&%!$KW2FNP"$<,.X][1$DJB0$+ MQ`CM';PR@&WOX,<(%]+F=AD.\RS]*9,LTQCZP^_UZ=*)W2ZF/$+IO#P-)%&- ME,*2K_4&#/:FKW5Q7'#L1%J_$]ZE1'VPNMD+L(O.FPJ98SEF#N`.2B**"Z4# M)"DKLRI1&^E"*<&TD1-4"HZHH=Q%#(:FS3"EC^8R/Q4S[JX`SL<\8Q\"HV)G MZD8,YG0-;%.]?3;'O4=[>Q8MZ(J17T>CNJ;]%TI*SK#3ZJ"U&':GZ(,C]$F$ M=JR@$I*\:']S#S(-8`G!%DM%LGWDET3U!G=JN,!>5QQ3>&[)E]3T]EV;U.@; M^*_;?BGTOZ^.GT([,O)SR0>7%E9NY?0MI;7^C_U9WP+Z5Y MPXC;FZ.S*3JB(&T)583O-"#SO_=@=-/9A)LFJ.;,NVEXVE.%4OW5,T%5`9<08![YA19`3UT0GM(AG3A$M24'_];5HX%ZF./)$TW:_)[D?V MS+96VCQ/M7YF+YE4MF7:P=RY1:M6L\D<,FX/]0(4KLVTR;C#J7FJZ=E,)-#3 M29Z!Q\V2X5^[%["R%.@?,)XXL80)G[:# M,&`\=_I22`>FQQW\-CI?"/6$K(#-A+%N[(];O)D))3+QYO>-,SO7JS_:B#>M M')?CQ&@IBRB_4`3A%^S_)[A')Y*M%QV?WOI*M(-FB,"EL&(JI'"O[:`82_`G MJ7TX2I'^]Q%317(V)69#+@[3XL&D)')A!&I6IHJ"[ M2>[H(%:8@C*#)8$G9*@T]V@L=/)\P$>`5+6U1E> M%W;'M9#*%E:<0#NP;,1?N;>=!&Y96J'I`S>&*Y3\%A-GEENQ5,RHPDQ_6NN* M)-$PJF%4X>$E%X;=P7*`HJF!4X2!)YB/K++F0OI0'>/,<6+Y= M4RIA5&'A)PG>[)"BJ)I1A9M?'C`.Z2U&%8TK%/U,<_:C!XX+BJ+2QA72;MF^ MCI?V)T5L7:I?N[N;[IC>JC'U.?Z^SV6^8GJOQM3KN+[N2N^-"'NQ4)#Z-FV+ MSV"?2WSOQI_R'UEO^)+Y^37V\W;@FR[VUUS*+CZ[45>:%ZVI)&^Z]?D_4$L# M!!0````(`)%\9D=GW3J5F@(``.4)```8````>&PO=V]R:W-H965T&ULC9;=CJ,@&(9OQ7@!(^!?G5B3:9O-[L$FDSG8/:8MK694.D#;V;M? M0(L.F-&3"O1]OX>_#\COE+WSDA#A?39UR]=^*<3E.0CXH20-YD_T0EKYSXFR M!@M99>>`7QC!1VUJZ@`!D`0-KEJ_R'7;*RMR>A5UU9)7YO%KTV#V;T-J>E_[ MT'\TO%7G4JB&H,@#XSM6#6EY15N/D=/:?X'/.[A2$JWX4Y$['Y4]U?D]I>^J M\NNX]H'J`ZG)0:@06'YN9$OJ6D62Y(\^Z,!4QG'Y$?V''J[L_AYSLJ7UW^HH M2ME;X'M'P-H3'`Z%M#U!LBRQ!T0]$3L<,"%SFC=X]?L-H>\%G*F0HB M(ZN"FEDY"5S.;]=Z*T`>W%287K$9*Y!60*,(9.Q)`'H`-LBQHZ^`K:L(ORIV MKB*:[T)HQAB.[*&VQ_/VR-BCD3W2]L2:(E>1S@-B`X@=^\H"N(IL'I`80.+8 MH;W*$Y(%RYP:1.KZK77>3$C"><3*(%:N/[(0G:35DKA;")`DV6H>DQE,YF)B M"S,A2>81$`Q9!]P(J946O68\F#"-00C``M0HP:&+LK;7KM=TJ*339%F2Q=EJ M"0P-,.3",OL\<35H"67(9QBZ$:!-F="@!90A[:&;U2BT*1.:!4<3''(?NJF- M[.TVI5E"&0X`Z*8WL@^Q7C/>;PC`!2#`+HG M`7)VF:L)[5T6C"[)AK"S?FUP[T"OK>AN0]-J7C0O^MX/!GF17_"9_,;L7+7< MVU,AKVI]2Y\H%41V!3S)Y2OEF\M4:G(2JIC*,NM>(5U%T,OC465>=L5_4$L# M!!0````(`)%\9D>TS[:0X0,``(D2```8````>&PO=V]R:W-H965T&ULC9A-;^,V$(;_BN'[KCC##U&!8Z!64;2'`HL]M&(1]2\D-:FVO=_&B/SG6KGU5Y;A_7QZZ[/"1)^WQT5=%^ MK2_NW/_G4#=5T?6GS4O27AI7[,>BJDQ0")-4Q>F\WF[&:]^:[:9^[U[_`0R[' MR)CXZ^2N[>)X-<`_U?6/X>2/_>-:#`RN=,_=T$31?[RYW)7ET%+?\S^W1GV? M0^'R^+WUW\;A]OA/1>ORNOS[M.^./:U8K_;N4+R6W??Z^KN[C4$/#3[793O^ M73V_MEU=O9>L5U7Q<_H\G!<`.K3`GDKD*0@FCG5R_OUI]`SA>84AE!HWH7**`9#R`+]15F>,)Q"+NU/@)0G(>23E0=;1%Y`(*04*Y<#H M&"*O7>#>5=2[(/E#JF7*@`(Q*U!$\'CU`G>OHNX%;E8K0&O*$XB!2&.>:"]A M6%IX6M=43`M>GL#MJ:@]@9LQ8PM;,)1%L'A]`O>GHOX$+D=E@1HTE`(5X5#P M$@5N4;ID[(`+4E"4@&EM%K'@@W2-DLA?LTZ#6*7*.: M:A2Y'^G$!")9&K'PHQ8$[TY43%3Q:P%Z%V'?,>IZ8XS ME*$+P>>9CTF\,Y$[4U-/H6&31G>E^>>9CTF\,9$;4U-'(7?A%Y51L>:A6+\E MC!`5>F MG)*+TU!=26Y%8R7[]1:**:TCUG[I]2FY/@T5E@3VC(9V,Z%88#>3+%X:7(H7 M]V?1O)S.[>JI[KJZ&E\]'.JZ>,X(`(``','```8````>&PO=V]R M:W-H965T&ULC95=DYL@%(;_BN,/"/@53<8XTV2GTUYT9FR(?O>\YS4"#O*'OG)<;"^ZQ)PS=^*42[!H`? M2EPCOJ`M;N2;$V4U$G+(SH"W#*.C-M4$A!`N08VJQB]R/??*BIQ>!*D:_,H\ M?JEKQ/YN,:'=Q@_\V\1;=2Z%F@!%#HSO6-6XX15M/(9/&_];L-X%4$FTXG>% M.S[J>PI^3^F[&OP\;GRH&##!!Z%"(-E<\0X3HB+)S!]#T'M.91SW;]&_ZW(E M_AYQO*/D3W44I:2%OG?$)W0AXHUV/_!00Z("'BCA^ND=+ES0^F;QO1I]]FW5 MZ+;KWV1PL#TVA(,A-(8@?FJ(!D-D&4!/INMZ00(5.:.=QUNDOG:PEG*F@LC( MJJ,62M;$Y7+UL]=B&>?@JN(,DNU8$FI)^+]BYRJBNP3(_`\A0@,1COQ1#Y', M^R/CCT;^N/2B8I4D.1.O[46O!M^I7_ M8T8T29(9DLPEL9)LLX>?WOY!YE23+"O#LG)9K(V]73E9HC2Q41Z)XFR>)(#W M4PBZ+)%]#,&OP#Q4.31@=#RVZ(Q_(7:N&N[MJ9`GK3YD3Y0*+"/"A=P#I;P! MS8#@DU#=5/99?R?T`T';VQ5G[MGB'U!+`P04````"`"1?&9'P:U MQ$-R>5P58[:2PU:E-I#NWIC:.0P@_[JE?TNH&ZUN M1?F].EE;.S^R-*]>%Z>ZOBQ=M]J=;)94+\7%YLTOAZ+,DKIY+(]N=2EMLN^, MLM250@1NEISSQ7K5M7TIUZOB6J?GW'XIG>J:94GYOY>*K; M!G>]<@>[_3FS>74NTA]?%1UC&4K5(1_QSMK=JGYW[O3L<_6<'K_\/Y7)[<9_EM2V:A(OYWW]:D9 MK5@X>WM(KFG]M;A]LG<-?NMP5Z15]]_97:NZR!XF"R=+?O37<]Y=;_TO6MS- M>`-Y-Y"#P=`/;Z#N!FHT\/YHX-T-O+D]^'<#'_7@]MJ[R&V3.EFORN+F5)>D M74^P;/"R==)X;F_:J6BB5C43TK>^KT-OY;ZW?N[(9HK('O%_1[84@8%PF_[9 M0]?;AR3OD*!#C/%0M",*@0@A1/&@E!(^GKF8H4`H_[DL?Y#E4UD&R?(GO?A]+SI` M$QA1R/,E(%44`BDU5L51GB>>JPH&50%1I052%9!>`H&E1PP$!J]="H&6!O47 M'C7BCDJT'J&LDFV`JK,Q\J`";+`L\53$BNC%("FTCC,B!G)`>2H35)M M`=8FF8TMQ-(H]`$$3@\L)?%BY"@E9FRD,*9-4%18B(4I.AV,,DHI;4@Q0BF` M$/#&P6+!K$D;4SK0G*YQ3@>/=B1P,HE8*E18&Z64P,LDYB@IS0QE8U8'FM8U M3NLPS;./&L,CLT8IJ25YU2BEFYT<*V,H%<[91,;,#C2UXU2[@6FNU1TC7C2( MZ1]@G9P-+94I)5^(3`Z2W@R98ZJ'D,H$+#/\'S(Y&RJ34HT"\@ZRU)QL-Y8D M0&L2@VL2H%6""GV%E7&4ARO06;YBWM>F#LY2>S.L"IG5USSNE^[0^MP M3O91MBBKHNLN[HYU`4M6T& M+UZ:&)]LLA\>4GNHV]NP#7Y_%M8_U,7E<;0WG"^N?P%02P,$%`````@`D7QF M1U)4O5T*`@``*P8``!@```!X;"]W;W)KWQOY$Q+&>";&=-I#9S(Y-&>)ZQHR1U`R_<$T=*,?];`&'=T@_]<^"U/E12!U">(]>;G[NE'V@+0&`KM0)6CQ.L M@!`MI!+_Z34O*35QN#ZK?S?5*O<;+&#%R%N]DY4R&_C>#O;X2.0KZWY`7X)Q MN&5$F%]O>Q22T3/%]RC^L,^Z,<_.OGD,>MIU0M03(D=P>:X3XIX07PC)34+2 M$Y+_S9#VA'24`=G:3>=*+'&><=9YHL7Z[Q0N%)QK$:6L%_HH5->$.A`;/>5/ MCQDZ:9T>4@PAD8',T\^0<@H)'0*I_%=-1&<3132A1Y\3K*:(^6SDX:[(^J;( MES9CUZMXP(\M?WZ?GSA^,N`GMM=/HUY;2&,@,P,)1IVXBRCO(M:W$%_6D;HZ MTDD=83!*4:23%-_&9SJ%C!#E?9'U%#(N!0VN`@5^,$-(>%MV;*0]1Q=U<^XY MTE=I%"_"Q2J\$B_57+1C["*?9RT^P"_,#W4CO`V3Z@*;N[MG3((R'CPHYY6: MW&Y#8"_U9W4C6GD>S^S[D_P!02P,$%`````@`D7QF1R_4VB%_!``` M9A8``!@```!X;"]W;W)K^%7Q5[? MZN9;>S*F\[Z71=6^K4Y==WGU_79W,F7>?JHOINK_V*3&%VW1`B[W\^3&:*8HC4]_SO/:CM37HOM:W_XP]S&$0\!=7;3C7V]W;;NZ?#19>67^??H]5^/O;?I/ M$MR;R0W@W@#F!G,_<@.\-T#;0(\CG9R-X_HM[_+-NJEO7GO)A]56K[V\&8+T MD8>+8:+Z,;7]=$U//S8J4&O_8PATUVR7&I@TL\+OHXM=P*.++;#F\&,'&5?$ MT?,>`^A%`#T&2%(R"9.D&B71)(D0R4`$$<;)")M;/C<2SD5@P$A(C,>M$)6E"G'`1 M!)&#E62VD@A6(F(E8;T$Q,>O%#\UD\%2$S@UE:*)%3@0TR0-J1VNZC.!RUJ!Y2:``"N'C`26 M=X#"D.C6NXM^7&_V2DJJ-'2HH,"R$R1VTNT'`A5#-L%4.:A5`3&,=TVD@R#T"%7HH4>"L4BT$\*Y(7@BTIIZLA$6>+RL86+ M3V`!H4`1B@(:YC@>:[;>KKY6W71$-C^=CTX_PW#\1YYOU6LV'8#: M,)OU)3^:O_+F>*Y:[[WNNKH6C&-&^N`[`DU>MC#O1SOO^ MR)BK.M#"W6$/)OQIT&KA0VI;YGH+HDXDK1C/LGNFA32T+%+MR98%#EY)`T^6 MN$%K8?^<0>%XHCNZ%)YEV_E88&7!5EXM-1@GT1`+S8D^[([G/"(2X*>$T6UB M$KU?$%]B\KT^T2Q:``65CPHB+%=X!*6B4&C\>]9\:QF)VWA1_YJF#>XOPL$C MJE^R]ETPFU%20R,&Y9]Q_`;S"(%$6%D?B>A'/;G<,/A8(%\%\HU`_I\1 M;V'NWS5AFSW58-MT=1RI<#!^VKRUNM[.AW2([`U>%KUHX8>PK32.7-"'DTV' MVB!Z"%:RNP,E77@_:Z*@\3'\%&([7:DI\=@O#V1]I>5?4$L#!!0````(`)%\ M9D=#DL!@H0$``+$#```8````>&PO=V]R:W-H965T&ULA5/+ M;MLP$/P5@A\0RK(=!X8L($Y1M(<"00[MF996$A&2JY*4E?Y]24IBA-1%+N+N M:F9VEH]B1/-J.P!'WI34]D0[Y_HC8[;J0'%[ASUH_Z=!H[CSJ6F9[0WP.I*4 M9'F6W3/%A:9E$6O/IBQP<%)H>#;$#DIQ\^<,$L<3W="E\"+:SH4"*PN6>+50 MH*U`30PT)_JX.9YW`1$!/P6,=A63X/V"^!J2[_6)9L$"2*A<4.!^N<(32!F$ M?./?L^9[RT!,BB\:E1M/F%.UX6!D=B>Q[. M;G/THO733]5KN=D>"G8-0C/FO,;D$R8AF%>_V2)?6ISS?^CY MY_1MSP_WG`KLDL%L)[/XSXBW,PX5?4$L#!!0````(`)%\9D=C5O]]H@$``*\#```8````>&PO=V]R M:W-H965T&ULA5/;;IPP$/T5RQ\0<]EMFA6+E$U5M0^5HCPT MSUX8P(K-4-LLR=_'-N"@9J6\X)GAG#-G?"DFU"^F`[#D5'&EG[7!@S%0= M*&YN<(#>_6E0*VY=JEMF!@V\#B0E698DWYCBHJ=E$6J/NBQPM%+T\*B)&97B M^NT$$JE:>!)M9WV!E06+O%HHZ(W`GFAHCO0^/9QV'A$`?P5,9A,3[_V, M^.*3W_61)MX"2*BL5^!NN<`#2.F%7.-_B^9'2T_DLZ]GIA(:*P/;UVLYPLU)Q:']7G$-UJ^`U!+`P04````"`"1?&9' M91YPQ)\!``"Q`P``&0```'AL+W=OX*7PPOO!A0*I*Y)Y+9>@ M+-<*&>@.^&ZS/Y8!$0&_.,QV%:/@_:3U:T@>VP,N@@40T+B@P/QRAGL0(@CY MQF\7S<^6@;B.%_6'.*UW?V(6[K7XS5LW>+,%1BUT;!+N1<\_X3+"+@@V6MCX M1B'03+@MHO'4*-K\P1RK*Z-G9$<6SFZS M]W`31+QR",+B".:XQ-&$R@GCUJRWHTN)(_Z'3K^G; M['"[HF]3]^WN:X$R"Y0K@?(_(U[#_#TD6>VI!-/'JV-1HR?ETN;E:KZ==S2> MR2>\KD;6PQ,S/5<6G;3S)QL/M=/:@;=2W.PP&OS[R8F`SH7PNX]-NE(I<7I< M'DA^I?4'4$L#!!0````(`)%\9D>3I<#IH`$``+$#```9````>&PO=V]R:W-H M965T M&,"*+\0V2_KWL0TXJ-TJ+WAF..?,&5_*29M7VP,X]"Z%LD?<.S<<"+%U#Y+9 M&SV`\G]:;21S/C4=L8,!UD22%(1FV3X*F/MV52E'IW@"IX-LJ.4S/PY M@=#3$>_P6GCA7>]"@50E2;R&2U"6:X4,M$=\MSN M;(91`RT;A7O1TT]81M@'P5H+&[^H'JW3HO73S]5+M2MH22Y!:,&< MMA@Z8Q*">/6K+>C:XD3_H=.OZ7ERF&_H^=P]WW\M4"2!8B-0_&?$:YC\KR9D MLZ<23!>OCD6U'I6;-R]5T^V\H_%,/N%5.;`.GICIN++HK)T_V7BHK=8.O)7L M9H]1[]]/2@2T+H3??6SF*S4G3@_K`TFOM/H`4$L#!!0````(`)%\9D=MMK#Z MH`$``+$#```9````>&PO=V]R:W-H965TU#99^8 MXD+3JHRU)U.5.#HI-#P98D>EN/ES!HG3B>[H6G@67>]"@54E2[Q&*-!6H"8& MVA-]V!W/14!$P$\!D]W$)'B_(+Z$Y'MSHEFP`!)J%Q2X7Z[P"%(&(=_X]Z+Y MUC(0M_&J_C5.Z]U?N(5'E+]$XWIO-J.D@9:/TCWC]`V6$0Y!L$9IXY?4HW6H M5@HEBK_.J]!QG98_]POM-B%?"'DB?,ZB\;E1M/F%.UZ5!B=B!Q[.;G?THO73S]5KM2N*DEV#T((Y;S'YC$D(YM5OMLC7%N?\'WK^,7V?'.XW M]/W8-7 MY<`[^,%-)[0E%W3^9..AMH@.O)7L[D!)[]]/2B2T+H3W/C;SE9H3A\/Z0-(K MK?X"4$L#!!0````(`)%\9D<-Q@<[H0$``+$#```9````>&PO=V]R:W-H965T MU#9?=,<:%I5<;:LZE*')T4&IX-L:-2W/P^@\3I M1'=T+;R(KG>AP*J2)5XC%&@K4!,#[8D^[H[G(B`BX(>`R6YB$KQ?$%]#\JTY MT2Q8``FU"PK<+U=X`BF#D&_\:]%\;QF(VWA5_Q*G]>XOW,(3RI^B<;TWFU'2 M0,M'Z5YP^@K+"(<@6*.T\4OJT3I4*X42Q=_F5>BX3LN??*'=)N0+(4^$3UDT M/C>*-C]SQZO2X$3LP,/9[8X>;H*(5PY!F-M;M'[ZN7JM=L5]R:Y!:,& M*C!=O#J6U#AJ-V]>JJ;;^1@/D;W#JW+@'7SGIA/:D@LZ?[+Q4%M$!]Y*=G>@ MI/?O)R426A?"!Q^;^4K-B<-A?2#IE59_`%!+`P04````"`"1?&9'E08V[J$! M``"Q`P``&0```'AL+W=O'!N/!)BFP$DLW=Z!.7_=-I(YGQJ>F)'`ZR-)"D(+8H/1#*N M<%W%VI.I*STYP14\&60G*9GY?0:AYQ/>X;7PS/O!A0*I*Y)Y+9>@+-<*&>A. M^&%W/)_859>-3B)V_=X,T6&+70L4FX9SU_A66$0Q!LM+#QBYK).BU7 M"D:2O::5J[C.Z0\M%]IM`ET(-!/NBV@\-8HV/S/'ZLKH&=F1A;/;'3WJUWY7U%KD%HP9RW&)HP&4&\^LT6=&UQIO_0Z?OT?7:XW]#W MJ?O^\+Y`F07*C4#YGQ%O83[]U81L]E2"Z>/5L:C1DW)I\W(UW\X'&L_D#5Y7 M(^OA.S,]5Q9=M/,G&P^UT]J!MU+<'3`:_/O)B8#.A?"CCTVZ4BEQ>EP?2'ZE M]1]02P,$%`````@`D7QF1^1&ULA5/+;MLP$/P5@A\0RK+=!H8L($X1-(<`00[MF996$A&2 MJY"4E?Y]2$IBA-9%+N+N:F9VEH]B1/-J.P!'WI74]D@[Y_H#8[;J0'%[@SUH M_Z=!H[CSJ6F9[0WP.I*49'F6?6.*"TW+(M:>35G@X*30\&R('93BYL\))(Y' MNJ%+X46TG0L%5A8L\6JA0%N!FAAHCO1N#X$^81]D&P0FGCEU2#=:@6"B6*OT^KT'$=YS^W,^TZ(9\)>2+DL0^; M&D6;/[CC96%P)+;GX>PV!P\W0<0KAR#,[2U:/_U4O92;?5:P2Q":,:ZK` MM/'J6%+AH-VT>:F:;N=='L_D$UX6/6_AB9M6:$O.Z/S)QD-M$!UX*]G-GI+. MOY^42&A<"+_[V$Q7:DH<]LL#2:^T_`!02P,$%`````@`D7QF1XI>7\*@`0`` ML0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0 MRK3<%H8L($Y1M(<"00[MF996$A&2JY*4E?Y]2>H1P360B[B[FIF=Y:,8T;ZZ M#L"3-ZV,.]'.^_[(F*LZT,(]8`\F_&G0:N%#:EOF>@NB3B2M&,^R3TP+:6A9 MI-JS+0LK\@OL;D1WVB6;0`"BH?%418KO`$2D6AT/C/K/G>,A*W M\:+^+4T;W%^$@R=4OV7MNV`VHZ2&1@S*O^#X'>81#E&P0N72EU2#\Z@7"B5: MO$VK-&D=IS]?LIEVG\!G`K\AL*E1LOE5>%$6%D?B>A'/;G<,SA0$D7WL^:*&A\##^'V$Y7:DH\]LL#65]I^0]0 M2P,$%`````@`D7QF1\9N*+:D`0``L0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK*=I(8L($X1M(<"00[MF996$A&2JY"4 ME?Y]24IBA-1`+N+N:F9VEH]B1/-J.P!'WI74]D@[Y_H#8[;J0'%[@SUH_Z=! MH[CSJ6F9[0WP.I*49'F6W3+%A:9E$6O/IBQP<%)H>#;$#DIQ\_<$$L+50H*U`30PT1_JP.9QV`1$!OP6,=A63X/V,^!J2G_619L$" M2*A<4.!^N<`C2!F$?..W6?.C92"NXT7]*4[KW9^YA4>4?T3M.F\VHZ2&A@_2 MO>#X`^81]D&P0FGCEU2#=:@6"B6*OT^KT'$=IS_[[4R[3LAG0IX(]UDT/C6* M-K]SQ\O"X$ALS\/9;0X>;H*(5PY!F-M;M'[ZJ7HI-_O;@EV"T(PYK3'YA$D( MYM6OMLB7%J?\/WK^-7V;'&Y7].WL\.YK@5T2V*T$=K/`_:<1KV&^?6K"5GNJ MP+3QZEA2X:#=M'FIFF[G0Q[/Y`->%CUOX1^=A,5VI*'/;+`TFOM/P'4$L#!!0````(`)%\9D='\?,;HP$` M`+$#```9````>&PO=V]R:W-H965TPY$T*94ZTMW8\,F;J'B0W=SB"^P*J2)5XS2%!F0$4TM"?Z MF!_/>X$@%\#S&83$^_]@OCJDQ_-B6;>`@BHK5?@;KG"$PCAA5SC/XOF>TM/ MW,:K^K4/P>&ML[LQDE#;1\$O8%Y^^PC'#P@C4*$[ZDGHQ%N5(H MD?PMKH,*ZQS_'(J%=IM0+(0B$;YDP7AL%&Q^Y997I<:9F)'[L\N/#JZ]B%/V M@9_;631N^EB]5OE]5K*K%UHPYRVFB)B$8$[]9HMB;7$N_J,7G]-WR>%N0]_% M[H>'SP7V26"_$=@O(^8?1KR%^>B2;?94@N["U3&DQDG9N'FIFF[G8SA$]@ZO MRI%W$/K;E"&7-"ZDPV'VB):<%:RNP,EO7L_*1'06A\^N%C'*Q43B^/Z0-(K MK?X!4$L#!!0````(`)%\9D<33'U6H0$``+$#```9````>&PO=V]R:W-H965T MK#[K,#`UBU M/=0VH?OW]04HRD;J"YX9SCESQI=B1/UN.@!+/J50YI!TUO9[2DW5@63F!GM0 M[D^#6C+K4MU2TVM@=2!)0;,TO:62<9641:B]ZK+`P0JNX%43,TC)]+\C"!P/ MR2:9"V^\[:POT+*@"Z_F$I3AJ(B&YI`\;/;'W","X`^'T:QBXKV?$-]]\E(? MDM1;``&5]0K,+6=X!"&\D&O\,6E^M_3$=3RK/X5IG?L3,_"(XB^O;>?,I@FI MH6&#L&\X/L,TPLX+5BA,^))J,!;E3$F(9)]QY2JL8_QSGTZTZX1L(F07!!H; M!9N_F&5EH7$DIF?^[#9[!]=>Q"G[P,_M+!HW?:R>R\WMMJ!G+S1ACFM,%C$+ M@CKUJRVRN<4Q^X^>_4S?+@ZW*_HV=M_=_2R0+P+Y2B"?1LPO1KR&V5TTH:L] ME:#;<'4,J7!0-F[>4EUNYT,6SN0;7A8]:^$WTRU7AIS0NI,-A]H@6G!6TIM= M0CKW?I9$0&-]>.=B':]43"SV\P-97FGY!5!+`P04````"`"1?&9'B1`>_>0! M``!2!0``&0```'AL+W=OOG'5J'S9:]SN$U+$!3M6#Z*$S;VHA.=5F*,](]1+HR9DX0SB*,L1I MVX5EX>:>9%F(BV9M!T\R4!?.J?S["$P,^S`.;Q//[;G1=@*5!9I]IY9#IUK1 M!1+J??@EWE6953C!KQ8&M>@'EOT@Q(L=_#CMP\@B`(.CM@G4-%>H@#$;9!;^ M,V6^+6F-R_XM_9NKUM`?J()*L-_M23<&-@J#$]3TPO2S&+[#5$)J`X^"*?<, MCA>E!;]9PH#3U[%M.]<.XYM\.]G6#7@RX-D0D_\:DLF0>`8TDKFZOE)-RT** M(5`]M1\[WAFYM"$FV7;L1IF:E-FN4=TKDC<) M,@"K%'BFP`M_,E'D'PH^21QY*>K_*)DX\E!71%G_B"V$T*\K:M61)O<1T&+W[^G9_A)Y;GM5'`0VIPD=XAJ(328P.C!%->8 M"VX>,*BU[>:F+\&PO=V]R:W-H965TV_>#.G)!L9? M10,@O7=*.K'U&RG[#4*B:(!B\`RX-B1(4!4&**&X[ M/\],[)GG&3M+TG;PS#UQIA3S/SL@;-CZH7\-O+1U(W4`Y1ERO+*ET(F6=1Z' M:NL_AIMCHA$&\*N%04SVGO9^8NQ5'WZ46S_0%H!`(;4"5LL%]D"(%E*)WT;- M6TI-G.ZOZD^F6N7^A`7L&?G=EK)19@/?*Z'"9R)?V/`=QA)66K!@1)A?KS@+ MR>B5XGL4O]NU[J:4!=BHY<\7$<9NFBA$;.; M8B*#6:\^0@Y+2.@02!FXZR*ZNMA%"_K,PWZ)6*RA*2S?AV7D.3;K!@T>484 M>&W^P,(KV+F3M@4NZF;$8Z2?X2R^"S?[\$[\H&:*'0$W^3SK<0T_,:_;3G@G M)M7C-^^^8DR"K0T">`0``XP,``!D```!X;"]W;W)K&ULC9/?;ML@%,9?!?D!BN/8R1HYEII.TW8QJ>K%=DWBXQ@5.!Z0N'W[\L=A M5ALIO3$'_)W?]R&@'E&_F![`DEG0RV9=5-] MI&;0P-K0)`4M\GQ%)>,J:^JP]J2;&D]6<`5/FIB3E$R_[4#@N,T6V67AF1][ MZQ=H4]/4UW()RG!41$.WS1X6FUWE%4'PA\-H9C7QV?>(+W[RJ]UFN8\``@[6 M$Y@;SO`(0GB0,_XW,?];^L9Y?:'_"+MUZ??,P".*O[RUO0N;9Z2%CIV$?<;Q M)TQ;"`D/*$SXDL/)6)27EHQ(]AI'KL(XQC_+^ZGM>D,Q-12IH8C!HU&(^9U9 MUM0:1V(&YL]NL7%R[2&.[`N_;Q?1N-W'U7.S6)`:P_I(P:%32KJ"GS/+]M4R:;\HK-M]N`*@&J+^2L M/N$WTT>N#-FC=7&PO M=V]R:W-H965TV$[;^O/XA##6URP?;PWILW-AZ*@;)WW@`([X/@CF_]1HA^ M$P2\;H`@_DQ[Z.2;(V4$";EDIX#W#-!!DP@.HC!,`X+:SB\+'7ME94'/`K<= MO#*/GPE![/<.,!VV_LJ_!M[:4R-4("B+P/(.+8&.M[3S&!RW_LMJ4^4*H0$_ M6ACX9.XI[WM*W]7BVV'KA\H"8*B%4D!RN$`%&"LAF?C7J'E+J8C3^57]BZY6 MNM\C#A7%/]N#:*39T/<.<$1G+-[H\!7&$A(E6%/,]=.KSUQ0Z0.>[61<*9$ MI+*:J(V2-7&Y729Z*5?9IR*X**$1LYMB(HW)$@L)I/QBCNB:8Q?-^-'?&:HY M(DOO9XAM%?&$'YLJTNR^P-H*K"<":R.0A\XV&$RG,:G!.)!J#GE@HQ+K(EEP ML7)QXR*;I$@T MQD%4<\13=-]%;EWD#WP8^:Q0]T3FB-PQ$4PN+`%VTHV,>S4]=\+<"1NUO?(E M4A?>B>]D#S4M[R93%CTZP7?$3FW'O3T5LIWH3G*D5(`T&#[+;Z:17=XN,!R% MFF9RSDSC,PM!^VL;M_^2\@]02P,$%`````@`D7QF1_EK!OK!`0``)04``!D` M``!X;"]W;W)K&ULG93;CILP%$5_!?$!8T+"+2)( MS52C]J'2:![:9R<<@C6^,+83IG]?7XB+*B2BON!CL\_:V[+L>A3R7?4`.OID ME*M#W&L][!%2YQX85D]B`&[^=$(RK,U47I`:).#6-3&*TB3)$<.$QTWMUEYE M4XNKIH3#JXS4E3$L?Q^!BO$0;^+[PANY]-HNH*9&H:\E#+@B@D<2ND/\9;,_ M5E;A!#\)C&I61S;[28AW._G>'N+$1@`*9VT)V`PW>`9*+<@8?TS,OY:V<5[? MZ2]NMR;]"2MX%O07:75OPB9QU$*'KU2_B?$;3%O(+/`LJ'+?Z'Q56K![2QPQ M_.E'PMTX^C]E,K4M-Z130QH:4A_<&[F87['&32W%&*D!V[/;[(U<6H@AV\+N MVT149O=^]=9LREV-;A8T:8YS3>HU118TR/`73=)@DLX`N\GD`<`V`+8+@/R? ME%[#G29WFFR[[K$+'KL%CV(=D`5`]D#(;!8R"!C M\3\9RV!1+EA4ZX`J`*H',E;KAXUF5V#`%_B!Y85P%9V$-K?)7:1."`T&ESR9 M<^G-FQ4F%#IMR\+4TE]C/]%BN#]*X65L_@!02P,$%`````@`D7QF1Y,CQUQ? M$```*ST``!0```!X;"]S:&%R9613=')I;F=S+GAM;.U;ZW+;MA+^? M4WF&DB7;:1PWS8PBRXU:WV+)R?0G1$(2&I)@"=*.^N,\Q&F?*$]V=A<@10FD MK*2=#)3 M:<0S^#6='^HD%3S0"R&R*#P\ZG:_/8RXC/=8'LM?9Q]O]=[T=U[]5++ M5R^S5^?*SR,19XS'`1O&FLM7_P\C![]?(0)YF)+]B5 MBK.%ADF!"#:?CD728<==CQUU>\\V'UZKAP[K/JM_^&,>-\]\8K=GF^/MD#LQ MESI+.4R\YI'8''4_Z;]A5\/ST:!_R6[O;L[O!Y,Q&UT/&I>?+!-'2J_;?MLX MX5:D4N&6`W;.,V=NH:Z__^UO=7FN$&>IB18:A_&_2QXVKC+=KMWU#[N-2VEH@@<9IPI_X/'Q@N>"LUN M\DQG8"P9.]NVTV[S:2A].)CB6<.0"QF*E`U@1W.5.B?H^[Z`Y_`T,".;]F=/ M>B<2E6:P(=@JSW*].?QGX7QD);Q3(<0/3^V.G&'7JF'B>Q&&[0^Q>@3U"*Y5 M#%L=:9V[>RT=IFJ/"_C066QSI/6PVK%OCS<_F:0\(!4LHZD*-Y_F6>1$=&V0 M>!@E'3:XN1[?7([.^Y/A.7O=O^Q?#X9L_&8XG*SP@^TS&;/)0N4:_,$]CO`A M`GH4]B=-3LJU%IEVHGS`]6+SLU'\('2&"M(>XP]AG/$PO%/7"3.5"I=E[DA"?[:QATCJ`P,MWW, M;0HPGX(/(>*)7W.9D-%KM_.#4L&C#!USFKU(<-UX+N$T#4LU#(.UN`^^EH<4 M8CS"Z/F-\'9W"36[G=Q,P)/ZX_%P,FXR>"CY5(8R`P4[5B]-EO`EVJCF>9K# MAL5'R)/:M5"Q!J$!`)>:L5AEHE'>NK4J.W-A8(N4UM6JRE<3CL M;K_3[<&14O;`PUQ\QWB>+<#O?X,A;?;,ZW:[3!/B?P=*M#\RB1`7,)4RU9@& MD-NU0J'X02'0] M<*N$RZ`-^.CS1(*;;8Z\$QG0.'1FGL:@Q`8HT37&?=)#6/_ZG(TG-X.?WMQ< MG@_OQM^PX=O[T>3GOR@#M&XY1LQ"9!+RU`%:CQT6*B\\94MFP"PM"/0@0B]D MS&-?8KY36M9AT,IW+1.!Y=D[=!-,D8:7/#G'LI=^Z5:[SJ"LOO/H+>QHG4WM M<(9:^M5\@-KA];O_7&*WLY^,)_#M:G@]83<7^/CF:DC."#_N5AQN,?(1'#IA#F'I).P4 M8($EJ9I)9_9-@IP6.9I-8`Y*CX%5PG./S44LD.0C?O$@DC$5.QG@CXLC&A#$ M7]#00#R(4"5UAS)PHC:WT+Q'@W--?,!@H!7BP*#5\%0`.1.HC0>I,2'#KUMS MW>W.(Z]%UK##H<53EACHIB2#_L5:4ZZE[VQVRX1`ACGD`6>*C9A*#FP27C>R M2>K-4]G&\9<+4*^%,M@_[X#;NXO'F_\X'+&6-V<7=SQ6YN MAW?]R>CZ!]8?3$;OB%ZXO+T\`!Q(89&E(*,#[8W+*,7/\3&K)MS`)7/$;S1(Y+:HGWGZ4^6@K7';.6:+'%@/??S#GPQN@;. M_L2!P>]](8#,S%(546$%9%R@M_KK]9E*T"G=1:NCDAR("#DR:BD%L$UKF#-? M%M3?Y!#4C_CHDUOCIT96PWH3P,LID".@5XQG62JG>88>B?@B/HK4E_II(7?@ MK.4FMG8(*IL-)-JE!C*?,-W,U#=;33>"L5T75`-:&`&FIS+&,D/+FU80=-0@0&]=1`!0)"G*`XBWPY] MDLD]/=<`T>:\U\"WB(#<8H\!XJLN`5#CQH'HW@$D0,'RF.<0I&"G65F#ZJ(H MT&S!'Y#"BA@,"PYC^C24`M*`@N119@O:K8R!G><^^1HZ(K"&B.'E@2'E"GT, M=1#F@2`"AKY/\U:W,C@271$SA@\9AZ`C11NFQJ-L[D$-):`G7R;8Q+2%0DC/ ML1M"FT3A]S$=C:H!`H0@&5Q-<)H%6?N7/*9CK,Y6JYIBL[HX MU6K5C"_8E0@D-;!3%8!:H):"@J##6GOWDZOS/>P>[>%8P(Z$Q\L])(UQ#N-3 MZN.CMUL-LI_(!7#P$MOF`FL]MZ'3`?DT2"50*9G&7\1C/J?M>O0(U4?+H0)K M#U4U4"4AL1;H!5R--*_B<&E``^R&&\;L1K&]FG``1,<76N.M`CB#SJ.(8\'. M9ERF,+UR]&]T92N);7]8\-1YF)%_VV0'F^C8&P_@H3PRB1S+%%*]Y7,((.`& M&$!M4\24(T'J(R1D098+.BZ8/++^RL?`=C'\[%:P,+9]RI#]B"&N$. M]`.@6A$RQN*(IX$F4U[QI6W4Q;"IBN//]R&P!Z`3U%13.R#N8AH&0 M#]9KC4@%(C29!N]O`(+1-+F!S0A*RR7ELC%LE[8LD.@O5H]YP!:N3E4]4;:FA7$03XLWT+WDP7X6/OPJ?]0>6 MO)?&"@J7TP:5*?C6\&Z.^%EN`];#Q`HR(IDAI#', M+_BQ#4`9RH$KX0SG=4)<05<8/MP M@7T(BJI]UO-.CD[H^^G)<_9>I1_:,FXG6`I`U=KSCGI'\+77/69W_!$R*5@$ MSHY/3GO'\/7%T1$SA=L^._%.3E[0]]/G1_6U[6N"K$&EMG744M[6E3$,V?G;`UF;9_(L-9=!R;UW+:FKOK#C;A^R,5W*A M@JQ`EW#,;!C"/OQ?')V@Q6G>*Q2Q4'<.[7 M8`S,'8HM1)C8X!,4W)_^I15E&."2Q&](Z[A[`*DOK\'F2 MA!+O3C!C/,*"R_9,Y2EK'4&`1^:^ADA8T4#Q[`XV]MEAYZM:L-2E79V4"=PV M##W$4=2FB51;?UZ&F`8:1GG&_("V@%J,, MRG\97GS;CA8^Q M[-XD5_'1%DSE<`6^.[=^2B$JH\+9/-2SHQVD^!$/R`YN3@-]N3G!J6E&S0W? MUG.3D>WC3K6ZR:@Y4+;O\?J=J@\PY*';2P:."D8Q),Q]+U@RN_"EV>`8/9L M=!R*P#CK2YZQ#ZP"-(HI<6JO(13)&HU+S]PBA) M.F);\U4C_YAA#5F>KG]4DC-T3)3T7VD^E(;.&3U7&@]N_.#SN'I)UW^98LV.M[1<% M.&$49.H/PM*-48!%%<9HWQ04K4N\#F8]X%:5HL3<,MY,,IF\5NUO.^1]OJE18 MZQGKNX1S7"%:#5K<.FLW)7WEG7^"=ZZ[_VJ05U`WC//+U8L7?EI9.Y M`FTR\E^WQ&X>\97K?A'0G>.+X*'>_9TT.\%QM35`U^P8'Z4$OYE&'H;4G;PET3.JQ_%VJM=5E9>?MZ:W_)V/"WD!N]26IGLNL^ M:]&OIFGJ&F::@8GQ70#3V[K`7E2?Z-93\M=;GW72/P?V/]\$A3R\>6?C#7D& M=2LO-.([;HQ><:O^M408P[_&ALN?@/[/2E]>PW9;EW5_L/&%R>"_@O,[NG=U M&8-B'K/HZ+QW9"%M=Q$.&VD>ZOR%8G5H54O>ZJBK*8=:9Z_^#5!+`0(4`Q0` M```(`)%\9D?[QI0%D@$``#$1```3``````````````"``0````!;0V]N=&5N M=%]4>7!E&UL4$L!`A0#%`````@`D7QF1TAU!>[%````*P(```L````` M`````````(`!PP$``%]R96QS+RYR96QS4$L!`A0#%`````@`D7QF1[:A'7%. M`0``Q0\``!H``````````````(`!L0(``'AL+U]R96QS+W=O&PO M=&AE;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`)%\9D>EA@7^.`(``.<(```- M``````````````"``7,.``!X;"]S='EL97,N>&UL4$L!`A0#%`````@`D7QF M1Z@("'0$`P``]@@```\``````````````(`!UA```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`D7QF1\UYXS@@`@``&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`D7QF1R_4VB%_!```9A8``!@``````````````(`!\R,``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`D7QF1V-6_WVB`0`` MKP,``!@``````````````(`!52P``'AL+W=O&UL4$L!`A0#%`````@`D7QF1Y.E MP.F@`0``L0,``!D``````````````(`!`S```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`D7QF1Y4&-NZA`0``L0,``!D` M`````````````(`!B34``'AL+W=O&PO M=V]R:W-H965T*7E_"H`$` M`+$#```9``````````````"``3@Y``!X;"]W;W)K&UL4$L!`A0#%`````@`D7QF1\9N*+:D`0``L0,``!D``````````````(`! M#SL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`D7QF1XD0'OWD`0``4@4``!D``````````````(`!G$```'AL+W=O&PO=V]R:W-H965T%$``!X M;"]W;W)K&UL4$L!`A0#%`````@`D7QF1]*E/'D7 M`@``5P8``!D``````````````(`!MD8``'AL+W=O&PO=V]R:W-H965T3(\=<7Q```"L]```4``````````````"``?Q*``!X;"]S:&%R9613=')I =;F=S+GAM;%!+!08`````(0`A`-D(``"-6P`````` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventories
9 Months Ended

Sep. 30, 2015

Notes

Inventories
(3) Inventories at September 30, 2015 and December 31, 2014 consisted of the following:

September 30, 2015

December 31, 2014

Finished goods

$

1,424

$

1,847

Work-in-process

1,212

1,103

Raw materials

1,813

1,922

Total

$

4,449

$

4,872

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 15 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

New Accounting Pronouncements and Changes in Accounting Principles
9 Months Ended

Sep. 30, 2015

Notes

New Accounting Pronouncements and Changes in Accounting Principles
(2) Recent Accounting Standards.

In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Direct Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Indirect Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.10-01.(b)(6))

-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Accounting Change

-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Retrospective Application

-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 01

-Paragraph b

-Subparagraph 6

-Article 10

+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 16 0001096906-15-001137-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001096906-15-001137-xbrl.zip M4$L#!!0````(`'I\9D?=TTH!BB(``'>1`0`1`!P`=71M9"TR,#$U,#DS,"YX M;6Q55`D``R@//58H#SU6=7@+``$$)0X```0Y`0``[%WK<]LXDO]\5W7_`[8V M-8FK+)FDJ)_GOW7Q57WTS_^^<[\8/[]UW^]N_J?-GE\?&PS>TQ]R:UM>5/2:B&DIWO? M(=`'5YRZGNN&TSTLV6IKOP*$K3YXHTD_=Z) M>A@WM5FJG6!6>^P]G,"#',HC[JQ`#P,ZF3(;98.MN]JPHRU0.-S]O-+ZL2-A MZ,/A\$0^7?0Q\-=*9'@"3^.&&9*KLL/']U0L9`>Z9!IZOTC:JL4"L^!YB*&I M?O+KAQ_OK`F;TE9ZB)`DWV9(07G^[7L$>2HDI5LV(E(0IZ@G;UX*/ITY2%;^ M;>*ST9N783"U6[%LVT_"?DE.))UH_$_?NP],!%/F!N**6XXG0 M9\1F%I]2!U2NU7E)+,\-V%-PBY0O]>Y/\*?0Y>KWSW<7+W_H=C1-^_YD.^)- MX3`S*`9549Q9EA="NUMF,?Y`[QWVD07GH>_#RZ5E80Y7I5%$O!D4&4F8?:TB MANM@POPS(5@@*O:_-QBNL,Y2K,,PT]5^;U"&7:VN=8R.UEN5:P.,,ETRAKU^ M=TLV$.1FS`_F-PYU@S/7OOP]Y#/4>1C?LMWK=U.R+"+>#(I,WP=&IU<-PSO/ MLQ^YXY3MM6X.-7.%94RI//E,=_2N;G8W$[_B\!;[D3\P^[T+7G_,P4+5H+_S M/2%**RJD0JM]VL2A.3@9&70RZMP4&/!JX31T:,#LLZGG!_P/F;N5UH`.!/-M M`:[AN4O(6:W2>]VM);H-X/0[8%N73Y838G)=U:Z,;J??3P7DS5R:A95UK0,- MDJM:H%2SLM(80"Z6Y]/+DLXZ3%WKY\6DW,SBALXQ]E<,?T/#R$TJ5JG699SI MX=`85F#KA\S^D=-[[O"`LZH1WQSH&>;YE!O@GTWC='-0@?M'+V`UASK!,X=: M+6[9^#!(Q:I-'.L/:[=OZBLL-TBT[D`.AOUR_#QW_(GYTZ0D:@QA'KEZ_+)& MVE^=<&QD><%&##IN?Z)/"6'$'A<2O;1C3O\N/>9:9]64:R/88W^R<]WN0-][ M;SYZKE7-X'0M%3LV,6@.3595A]WJ4!(M2LM`5\E'KA>HQ"2;&/:ZJ?1F'8L; M/^KU7>!9G^7:"'D2_-3%M;H`@LSF#J56E$I33*-/T3OWIE//31`K.P=:33[3 MY*KSR@:P$IP2V;A58[A!P1G:MCM$QFX1KVQRG-]2YH1Q\WCF=\8`ZB3$I/8_II>+&9A9-(LJ9 MP@RU.GAN64"YR^Q+ZKLPQTG.#\$3L:J2]W,HTE(&1'US$&O4P>0 ME-K$S2^B5>A53=VW5Y15S:`J,N0 MJN(HL-LF4$1F55X2';D-4@1!D:[-/D\`G7YJ6E")>=(N=R&`!/UF@%03Q3H8 M=]1AXI8],#=DQ5N;_\I=0!^F-@-3]"KS,O-67/JI3:UFF%WH74W7]/^-RW92 M4V&MV]]%%R]T4W$U<[GJ6F=[KN>>"*Y'N#(F[B`#+#N(G4&OE]*>%7J5>>4, MHMDU]!WP*AY#W3`&W9UP+1I#W3#-M'-8SU5N$]_XWJAP:I@[?CVMOSJ?3]"J MQ"-GW'KZL-<@CPWC-3!2*P)UN16.TZ";6C]=Q^V..0YNHC*7^117H,_L*7>Y M"'P:\`=V^31CKBA::LL=/I#LZO!MQZ9I9#F#;J05ZSF0%:M*+[T'\CP0B_2K MUTD5`%6`>,L$H[XU@<87$`,<3Q8,554X?=6X"HDW!",OGNOI);9=PRA6)3-5 M";HB.=ZQE"5W''TL&C/)5=#,H:?H5B#7YZCT5,;YLWQV^`^S%3^ MVB3C0J?0&PRJ,%YN%Y0=4S,]7R'UIH#DZ$!+3\MA#TB*-:.E&[UG@%2D+JU. MVCJWA[34IRO?FYX#3^Z&\$:D<)X;;2VJ=I_H$Q,?N.OY/)B_!WP^$X&LIDA2 M45L('U@P\>S$L8/23B>MAGO$>I`RRC&0SB`U_?BZ9;3)J?=3]8M?N[2*@U!/ M.R3[`WJ1`WL+DY\*2QVZ-D@7.^?2KGL!43@S,8P\ M&RP&H=93JF2N'(EJ2H<\N8?@U0QWQH.<;%%O,GTE@IN%>UH9?JSNJD5.PC#:'6W',-:I\BH,PZP#XX([8;"RB=6D+D34 MZR.HK`\-(=A6)XSA'J!LJ1=&.2B_,#Q;S^RS!XBH8_8QG-XS_WJ4V89+*^XF M5YC8M-C>-Z[J[G+?X9W5[.Y0E? M6-1[W+,KV[^Y5<_KPGK^ON2M4W72)WBXA;-@T'Z:6X'<-IG`CO2J8L@$H'7(J*%*-\)?# M?:^]R5')/VUOBK7[3]RMFOZWZ6Y5]>=54BQCIR'VN7N<6YOYY79X0SKU97?] MF9*H=+>WVDPK'JA!K]-I;-^N6#"#3C]ST5\>JPL&\K+XIAO*-A2*]M(7E2R) M5N-6U#4SM1ZVEMO208,3W_(JMDUU^,/4Q0OK6#0`I$@&AI9:A-T.R%+UFR@] M21X0R"-GJDB$E#<`JE8U:$$U\;U'3-2JO3 MS;^G:INRD3J@BJ6DI_WJ]J#BH@!F8P2&5O7\;.KX73[UN@`*8\RP+`"0$N09 M@ETP]?_W;O9"YLKRZ`]7+6H;9LVB*PQ&S:.3R=RR=8V4*U.AMH%3D\"*A)8Z M)ET;&`8_-_#\X@O%-OGM[J:13+!I"%"1D(:9JKK*<&Y\-J/\[FMO\F[E;(>K$(_F/DZ06U:W'Y`83E0MXG[YR*B)5$*Q/XLQ6QY#PMN>\/-2UZ/SK6XB+1:F,CZM,R-*%O`N%DTN>`86UR[QI1GF%HTSB%>BWGQ/57]SJNQEN.X&;J%P>RD]J`PWOXF*NNF%DNK972=]868)KKN!6^CY!JET MN6&X9V`'OC\'E:_PL0A]:*0`E7>YEMY+K3X_!["\ M"PX&QE96400L<6\$?KNAQF5LG347/2C"E9D6+_$-,]L"!4S5=1BUNME+W_RR MI%F-66'W.NEEYS7`]=;!R6Z!0'[XS@E>_Z758N.G5NN[_,=G7GB]93Z M8^Z>:MR-_MFZ]X+`FYZVH3OZ+%"M\-U7^A'Y-&'0;QK:'`^`CV*`0#%&2";T M@9%[QEPRPUT>2+$)=PFU+,^W*WAM!2[4ICRVA&9CC0C*"^$PN&_U7O::^QZQ!D$AT5 M$R]T@`<#?E2^#R/Q6^C*#BU[F2ND&+:(^[?D']`)^?)* MPOD]](+7/W_Z<+'\13R?+'\A&:PMH.Y\^<9/_)"!/ MR7S.J$\@U04X$.`8'@8E'?V8X$?:D[)XK[!Z,^YB7V%O0(J"RW4I``DC!-1='&^$CM_8P@>)%XZ("U"%H/XXL:>-HG+M0F=JLHJO&A? MCI87"HJ3#O:$.D3@G9:0U_`O6@+5QPGX`3G8=AO-[V2&QI2H-6W8'Z0R_\>S MA0&`-KGP3TN]BJ%')H]BL9QC@B6*7@!F2)"$W1M:EOPU`L MY5>+#ZCO!SJ76GT,VO.8=!+CD$=NBH*.JLOS@PD%@PD#A[M@L91@>2],M:UD M@3"9>C9SI"4!?C69`G4,!8O=7\0`6_CJJG'0)%DJ3$:^-Y5B]BE8N_(=%B@X MQ$=?:9$(0;M@`@54IYX(2/PINY@2F(8W=I4NQUTXCFP,.7#7!GK^O"5F$.!& MW%JT:DNGON@V%^0>5^;00:#I+)RFD@)U5??FL?N+&/_!%E"@US:;<2N0[P=X MR&$$?@2L:HR7KXH$L@$OCBDP&HOO M9R5B#J'WH!\2BTL#^,-QU`_PAGPJ/18,(MJ>CU^6"J176V@!/+(@"R0CQWL4 M*:6(I+/4CN2H"@ZBA\&D(+#?0GN\#"ZJNU*FJP^HVJ)9#)L=*Y]0/AGURD8) MCD)GA!],I@O620%=QCHNP[T*!D$4"T()GW&LY8#7@1"Z[L#W4/?P$F:4.D6# M`>S,3CVCLYGO41C8."A1>TE:"A@,5D0^877,0'<7@W;/,+L$WRRGRD@8Z:W$ M0)D3R%D=Z#P#A^'*@1I!XK8,?WI7AK^>%!Z$1TP98D#`#U,4H#'E@?3O2S08 MH+%!9*CX&DA>2-'()`8BDA6I>8#(XRX1^9EJ*59D`:-B+:+"NIP+8@PV17X2 MG%)Z@-U/^LSDVDS]L)!*H57MU/Q9$]3.$4E6BH%D[S"W4VF,)L>Q*\T;.0Y8(W0]=.&@LY2-U($`[EN>P_I,?/??">3-4W]CUC,<03H"<#( M>3)#5Y1YDD2GB+8LZ`N="78:_V.)2B$`PW#`E424'#8*U+^6+5`M[6`2M="' M1L3M(?EBX,UR0,@73XTVRBB"?*JE$#0NU)/`7@=^6!9ZK]V=!9$L3UW/9;%< M(U32.(&%:WN/J.A$;VOPPB'T53?-LKW5VUW`TF!ODXPQMV-^#N]-8GB-K%J2 MU&E$9,$G:^0E!*27E<]`:L,A#.Y7I=M^[%_OVWF6ZE&3CX]5@ M-?5;T5APT8]-HTBE&W+.>QC%Y_+7AZ6?#3GE@]+0@=D_.*?;]!C_XOF?6_!\ MAO5M8O@MLM?213"BDW MI\Z>,\MM9AX'FKCL;Q7AP%(!O<1M<37-+7-PYQF_KRZ6E]6!2&R\:N(B=E_?79W'O\8O#XB?7UP+#6&RPTT MR26$.UR$AZY`LW4?B`%P]F3!G%I7P,+*HX06C[+T6)#X5BQ9PQ:86R#[M)E3-\"-6E&)9U9S@-3K0 M?H0Z<,7N_1#+8%&A\@M_U@Q4^G@U%AW_0GVTON>MZ.D=D1@'P4^T^P\9D20K MG1>"O'?4#N)C_#(7IV3I#65Q5O1,R!JK651I+2L2/5E@+NL1'6>Q7A0;G6R# M#Y9LHK=)7%RI2H=EX:$L/XL=GG1U&"XFZKJ'8ZE*JEQQY#.FU,AF(\D&7E_P MEI7$GO]Y"J$(7E;%;%'UFBI9XCYT\U5'.P(N\RA^A+.9PYDXQH*[X!$8SELC M+_3)*P-B:.219,5J?/_$<80@A3,I0M9AXC[*24UD"CCI6)E+AN;(F"AV2&*F/DT124K*1=8(!6(,L M^<1/0\-31'03F9!/9)7M*$3Q8A5K;%HSGUL+%8)0F$JL&D_1JQ*4HIQBJ2C\ MAS7'"UG[R@RPQS-UME(-H0CX5%8(JE+.*%T!1^'PS\R1@=FSK-!7];Y1E:W2 M'+$@*@L(L;2>V3"$RY,4QRJNRVI<.:XP*%A(B>+W.9-EQ&_CT"Z?N]29"RZ+ MZ8$!5N3A@89%+RR'\JF*Y=@\1J_J(=E35/^_:.Z!I8TCJY+>CT]CTSA&-@#Y0[:+/@7OR6HPZ(3 M%5AGB_%5ELWC<2`<9$Q08.:E]`\RWG`:RIR#>+)D>+6NGLMC8E*3J8C*,D6] MHLP"07VKTOQ6I;G_Q6:M]$)&?[C+VK8=+&-T?BI;F5E:>0?MWA>[_/9->P]` M>[_*:LRWU%&'R99'9"!JJXQ_OP9Q6+5O^5JO*)=2_$/:_=/VX)\/=,?WFX;^ M&32T*('8A0O>(*TF\^7XKXCUM-LVNLEQ)[?QK$Q.Q.0J36+^E;Q%8.FG[Y7K MWKD-'(+YUM+V9U/G__N6#W]3K'TKUK/YR9W%QV+7^YGL<_I$QTN2R#HLS!?4>ZH'=[AN?\T1)NW(-+CJ`_:#`[@7?M#.N M#G%Q_>FA1H&HI*&D-*-.ND42B6"2Q]J#DU#U2C*5XC)^AIZ&8Y7:9P+1 M6&!YMFUM?7%+7HI&)X[7C@H2>I.^T*[7?*'M\8)HG]+O6;9*BV3PT\)1Z"0P MS4NWQQ(GAJ-/W31Q`@L0LD/RH@6%J81[FH1"6?YJ%O98D-@F7&4T*@W2S\68 MS/--;:;(35S3,6Y1N%`=,%.<\GBB8[OA*-K.KOT^Y6I+6*.$)Y+C-:]M7SR, MUWA-#,FE'Q0,D#DUE#?W?MEA8O]8CW3X0&;NLYZF#O#YIQ'W+'<-L`/9J39J M50BG/ZPN^("E!$T80>NXMV*QE_\1ZO>!7(S:^13)@.R.TJMKTO7HO3&_2. M5$$\$XHXQHM.ZA2\\S"COV2]RIW,8/8X-'L3Q6/]&),;<\7/^/$+N69)3XY& MVMNR1*-3!Z,#1@>,3E[4"IZI*7Z&/VDZ-V:F(:3:F1S.=-8?319\]820E-++ M!O"N]F#N"!4.O;P#*XL(%@-P%@/.A-4Y'9UU0">@$]"Y!3KA[B^`B(0%2%8X%^^JQ18FN/QC; MM9W*R99/TL\1'F#))GN7G1QRBNGDCK/Y?FWB=C^=,2[L(]I5M%!00.^GVPPDT!L84R"!YM8T\J`ZD$#OD6L))-!\GR)P MY@H`"?310AY(H#E:&8`$>D_.&GCGTP42Z$."+)!`ARQR7`A4UA>A@;>G/8?4 M;:@;$TE%$S,=O`F%=ZD%N\0'@W5%626`/3N+WJ/\HTI$+5M@OHM$HWR MM$.'RQJ`4*X1>K04%T#4EB/:N>33`G^8"]4/#UA`U`9$;3E[#QQY#$#4!ICD M#9-'Z\4"41LWTV%_SM[`1P;H[B=T@:@-B-I*GQ3[P%T%1&T`]J,!^VZ(VC*$ MT20D+0@E+NII\HTBO2@J+9R8Q@@R&X1P`OQB!^Y9>*M#L M`;^8S^@`OQ@8'3`Z>4TRX!<#?C&G,/"+'=[5%N`7`W!R"\Z#(\D!=`(Z^44G M7%D%<.XE.+,GU]E!P$X@%,A-UN-D0_^')$._0];X]0&1K0OVEF4T51:2:OXX MJ31.`N$^UV+K#WZTU!3V_Z?)X.2GV*PW<6]XVF>H8Z M:?9H\\5:8^MZ'Z2/6R>3Z<8-;HL)%?NE?K'>:',[ M]81N7E\KAL"FC6PVFYWXZK"P[6J)-*G9ODAH4KB.GHJG.*%&FLPE`UT1[K*^ MOGA#FDF)PJX_R4>44OMS7!M#'9JMDEWKU8S1JU6Z7J&(QY""Y^<<*-AD"C;C M%`QA=PL%!^C%&FFF92Q)\-!0FJ(>XZQ;,X_^>Z-K,SP9%T3`X^H-5?YU?ZL; M,TGKSW&]5Y+V]ZY'/][I%HHN,C7ZQU,]28\BE,7?RKIV94C:=!ZK;;W3:&;7 M]E514V)ZZ1WF)_>2W#^2HMW@)[WI=+E8JF3P5$W%]L&T6#17>M/J$5U9M^Y4 MAX);U8RVJI53H]:'8%.I3LJ.&WJ_7/@TE4M-47^>/RUZ[R!X?O5RA[2 M6LA,8J",*\E.F3W$&)'49R0960:Q4A'KE8;(Y"9)"'>&OECHVL32IW_I5L\< M8R@3SF62;L.;#Z.[87!"C,26*-9:/KBSXMB7N&B18Z9`?Z54$M+G?OFB*M.A MJDM66O7Q.Y9.Y[S3ZK0#=?L$AJH:*BHR^KA+9KJ1C@*\BB"54*PC6:"E_!4$ MQ(1[EPW"@T.L/;$D:VFFUO6,S$#7Q4H(5?-O7<5;1LE@NJ3+O]/]XD,E0W+_ M@U3UMZ9_:!.\F.D:DD>FN;19U[/)3Y`0L50>3(?X27H+B*T*6JE0Z03IS):M ME_^G$2?=5YK*MR4(BNSL-,GC;UU$VTT_?^LJ-*#Y%2\8@CF=8V?@Q\G,68S*I/:)=E3G`JT,@\LDB?-"NUL MJ/?S;M76.4;_1MG:-QS;M;GVH8.M,AJ"538L:EW90(CX;[?J/66_0K8%9K]A MBRWRK'+FP2(N^$6Q8(C^.;1BG8[/NI)#7X7`_ M!M5/&!%_D_9R(')TN\H:B/I>#D2.'DQ9`]'@:B"<,\?2W701;Z5:65M`SBBI M^O2,DOYVP5:!GXJI-^OBQ27^IEMU'E(!I%"PM'.\&A!@TH=KRSZ9\CTRJ`1; M@*R\X[;;;2._NULNR`&G;N-MO8[?[)I"!:FP`=+TA:+%B8O1V)$4+M6M>EJZ MK6)0Q!_^#U!+`P04````"`!Z?&9'RO:847<*```'B```%0`<`'5T;60M,C`Q M-3`Y,S!?8V%L+GAM;%54"0`#*`\]5B@//59U>`L``00E#@``!#D!``#M76US MXC@2_CQ;M?^!RW[(7=40DDER-TE-;LL!DG!%@`(R.W=75UN*W8!NC,1*,@G[ MZT\R$`Q(?F$V8YG^G>G\\7Y5^WFO/^/S[=G]V=W7_YY>_.?H]+3T],1>$/$PKL=N71< M*I>52CXF7R_5GT?$H23!$'YU,!)B.U`D^G2_&3RI?[9L\=P1B5,>%"H9H7Y/B2A]\WJ1OB2G'+DE%"7967 M8F7U5?GD0_GTY.B9>Q%%!]A?NTT@T&@,GK)%1=GN^.+T."*N*LQHB:TB"UN< M7%Q<5,)?H]*R.D^\B$=K/Z_,?]R0QC'JO-A7.+#\KL1@\'502#&7GEY&\7*3SONW^\"R`>.`M-5"@7@^ZTFFAE$_=J"*'OG)MR@ZCECB,DCU`_#$D,.#E(4(3 MI$ M?7]Y7Q\]@G]UF*EH)1]8-YC(OJF)I^!MJGG+*.<&2(G%HG`BKN.P=62(N%1(4'XW%86UGJ,%Z6'S`ZSFCSI2HT`[!2P*6.=*+NCV05E'G` M%H/0$ZC187YA'Y^.ZP9CQ0-XSI@R@7\/C9B=85-%>\BYT69Z+_@0]8)RCFXP MU]Y`[>+'G%1+Z"RU'6(>WK1NPJB_K!#LT!?8!25=DTGA[#GZN@SN)\#$K.,C M(ASBU7\+\&0,1$@P!B>++6(O6_%(]2R=6L+2'%4U8$SJ&]LQ+67LY6$#B][P M9[88WG5I0`3O@@MXBF13E]Z2P$-<$3MHV0"PQDXL8+O#MRKB(]FPU8=JW%/D M2Z6Y(ZJ(L9GLDS\C/P`#:^G*6D]?2A/8/28UR%1J3=G,/`:MB5C/RCH@NX<: MI2L7:ESD-PBST&%JF+L^Y0$SM9Z$0H4@*`ZTW8-46XR`I0D1-(+64Z,#IZ?C MW!(ZFA@]8A\+#`ET:`1S#G,Z:*:&_'0!SH9PWIYD-KLNOME$:G=D([5F`7BI M/'SU'M&E1 MXL8Z4F(QB[Q*YT[)L.WNF_7Z+]?_Y&1LG@[#`0V8DL=>=@R"8QH+)M.3U#WZXCZ4D6N%H+$+'G< MTQ>SB*A87`;V;!\]4A.U)]3HI.SNQ2.[V.%:A$IR8S`"PO$4&L2E8VA2SJ]A M0!G(L>S$/"?+6$_>_*9C=`?[V-TD'<_#<]4Z",L@I(HF6"!?XAI3$MK$Q'!R MP8)0FL("=C?:B*JQNSZ;8L7@9QN=W=/O#EN$^HF$Z"2+P8D6H]TA8Q<$P@2\ M.F($DV$T7TO.S;"+34L.*0H6@[0T%LBRV?"IL@FX*:^_3X9SKR__WM=;_?:- M_*5]7W=:-?G1Z=;OZJU>XW-]_NWK)3^G5<"6O.BT^N:4Z:<29CN,#HRM,"J1 MU^P%^<"[,`42@'FS?E,J[[Y!8]JU*TEOFP=0]B1+U(@H(Q!>/[:9!7GL,<"AFNM#0E.F@D\_;X'%QD+8]"9SR[ M>[9P.:%%"5U7O?X\`<)-,XB$0F_="Q),:O>L?CY>Q+3[B$#>1&_KNIYP]AW= MP.Y6_@)QX8370,`<])JDBT"W!N,N84T>\&*&WK7#/=&HSFZW>T&TH"0QE'B1 M*P@7&H"6!]&:G0,Y_VH/9+LQK]\:2^09M!CV0&YDCXZ'9+ZC[,[Z#!&.W-!Y MB!=>+5S)^V\P[[T3\+_2S?+V\!2.L!74O(+)"W)`,:.UHB.5W>&>B=<'P@#Y M^'?P[J@?'K9$F"A`;=(#-V#S'6F&N?RI)B_)L`,,4V_'QO3-MRN8@[R>V>W> MI>H"!VE6=7ZJ!E/P:7@Z-'ZV&5\F;^*-,<[Z'D@L;+NCN![XOO)$&4\SI'(& M'6^,">9"X9XF+!6D+%P(%M,:(DN/G^=NEOR_5F_UUG9IJD[O[J;9_N7UMK!B M[VK+OE6LDCD=>P"ACIS*T&**)?3KV0-7CP.YP0015[JE(R.N:5SZ?88*\DS4 MZ$DD%TEDLK))M8%@1EXT;$N+K#G7F]6=@+I9&23Z@D5A# MLC>#&93+:" MGKZ_VD*?`?9\2_$;@GE=!3F/`GWJN+\%6.VSICJ3F5S.4I^-(4\W0L38)46X MGJ?S;B$P/O8M+<7F"O:,ZQA+6;YQ:##$R\+9KCV6KH+_I[[LZIQ5E/2% M;S1*EEG:#JU^CTRB#0P+\KR.5S))AK'!EE.;FV@;9..9=N;,V81R>7/\&O'4 M1A9NDN7L#CBU`#8>E)>%_16*6WW>V8RQE]Q[5 MBU>P>UFLP8>#BN*:$K+_=$;M8?<3GT.(ZGV*LJ.IT>!1 M#`)_&5J8E^O,1?:=VWA[I=@>RS/C=(087*NL)I4B+3N8N!9K$-YW?DTVTC/[ M-TN87:6S)Y^VU\ON.Z\&"^EI_6C+[M!*ZQKF$\K#1YNU![$;O?%EW@[/6HOI M^;ZPA6_S-'_U4J/,:R21HOO.?CK[&59*CNWU@O!ZRO6)%W"J7V MA%25O3T726=C@^^\U]7A(G^]Z MWFS'NWV?\-P+FH:9Z*3:7I@P?8!>>?U:G;-DT9N1)+IEWYZ(C0?N6 MPSCTMF^P+2!TT=,]$L`P\A,I6Y,M#$GK".W>\WI1^A?*OJHQA[I@3(0T"!>& MF`V,6;:JC`/GX@?UYU$.V_*;_P%02P,$%`````@`>GQF1YI5)]':!@``-DP` M`!4`'`!U=&UD+3(P,34P.3,P7V1E9BYX;6Q55`D``R@//58H#SU6=7@+``$$ M)0X```0Y`0``[5Q;;^(X%'Z>D>8_9+L/[$H3`J65IM5T1RF7*2-N*LQE=[6J M3&+`FF`SMD/+OU\[)324)(3BA#":%QJ,?%"J]<^FK?, M11QJC(SX/:#PK6;: MBA:9:KHN(3D(?[^4'T/`H":"P>SJ9,+Y[-(P9*.'(76*A(X-X:-B^!5/WKQ^ M]/M4KY>(#LP-`1\A9<^-R,)E"6W)A2.Y*%Y52H+HTN",3&TV67)0O M+BX,[]=@;6'.YJOJ0>OGQN./SVJC&#@K?H6FKQY%!=2BQ(&W<*0M'S_?-C?] M(V.: M""#4#"13>]JQ')%_-S_:V*[CCGBBR8>$3KUYK_M M$;A\:NN^<0]J8MN!*$1W01C)TI;XNN84/G"(;6C[;B5^U5$JX?/SP+QIUVO- MJMGJW79KGZN#?K-3K78[_6ZK63,']=JUV3([U7K_IEX?O)39';UDPO'+,67% M=D^L8#"?0(XLD""-J*!^W64.=8@$F*8H_8'X;-<[@VY#_-)MU\U.3?SIW=9O MZIU^\TO]L30]B9("R(E@+X";`_DR&FXO0G-[7 M]-2,]9H3U9)BW&-5AICE$.92>`T88MU1CT(FNL!^R[%8H]FLPY)"4$%=!]Z; MED5;,6U;02B9_-TA@S]<8;H^5\/= MAL6L)_P8_P=>!,8T[1$'60OO4\E2)1.4Q[.L?%%,BM>?\M6@[3JP._(+%U67 MRGWX0"9;M>O3K#`/K1<*B*'3*4$29T=+@WO M`BVU-/W4#U8_FXQ!;S"W$!@BQT.T;&)W\:U$*8;TV-OJJU(L16QY6#`HCR2S M6;$&N>BE64V+OK<\SHLAV-+;^"NC/=Y\+HX!4B(VN(=61F>8T0.>#?@0)((E M!(=80;\%1]YV(K00#+,0O.DP`FSHW4UPF3X&8":=GQG0X,?!LC2J:11/J.R1;DFLL$"C*3>(%3T`BU(5U> M&GR\B')I$]9B$:BTKIZ?7\WM%X6+%];;TNFRWKWDLHD#5WAR$G`O\!M$WQ-`;8FR06(:'5L"D0% M'R[!Z>$FKU7J%*LRV!2/4;D_I.*!($L9FIAQZEUL;``+FE-Y;Y*FV)N50\?\H/8AT/[:N""!AN31K/.'C<:Q@A MFXT#'-H]_K0 M6L3LU).T/(J->R(*CFX?'S:J5C'%[A^3M#ST#G^';ALJ=1PIN=O]IRIE'LX% MTE,SXS.#]/1FJ_P6NLG=J>E!=R4[=.9M6F]RDM^A>[U8/=X@2`5ADT4+SJ&3 M+,/&-3ZV)!M+1/3IQ3$-ULT0=YZFHVWD*/[JS>#BTCD$?7/X)703'!_GH7M-.[H&6Y M_)#_,4J4_`]02P,$%`````@`>GQF1XT;,XQK(@``1[$!`!4`'`!U=&UD+3(P M,34P.3,P7VQA8BYX;6Q55`D``R@//58H#SU6=7@+``$$)0X```0Y`0``[5WK M<^2VD?^<5.5_P#FN[&Z59B7M>N^\?B0UJ\=Z$NV.3C.VXW.E4M00(R'FD&.2 M(VF2NO_]T`#)X0R)!PF0Q%[EBZV5@.Y&XP<0:/3CFS\]K0+T@..$1.&WSTY? MGCQ#.%Q$/@GOOGU&DFCTY9=OWHY.G_WIC[_[[3?_,1JAZSCR-POLH]LMNCA_ M/[Y)-B3%*(F6Z:,7XR,T]A^\$!J<1:OU)L4QFH1A]."EE$-R1/^Q>'E$_[;> MQN3N/D7/SUZ@5RG9R^03]?7_]U_#_GEV_F?_[A_1S+B]7$0K-!J!2`$)?_D*_G/K)1C1P83)MY_=I^GZJ^-CZ/1T M&P_/3XKQ^N9HM[O/)&)$Q2 M&!7OF)"O$O;[JVC!QJ7!$@E;P+]&>;,1_&IT^FKT^O3E4^*7!%V28(_-)O7N M5]@'71R#[D[>OCXI-0>"#351Z9+IXO3MV[?'[*_EUI2Z;@O&:]Q3"+_(FPG M[$'OGJ6>I5Z<&LA=ZM^;Y'.Z#>)6,I=Z]B=ME'I!.VEW/;FT?!.%7US1G_:$ MQD\I#GWLYV(#'&_>V+8QRD2?X;^%I\,3HYS;;)WV>__ONE1^(?O&"#/V`OV<1XAK3P2YFS9>+]]UJ3G<7E0T'UO6#%.HDV\P`<,Z/_^WD(\INAG"D4# MAV?PU:/,X(.-P]'WLV=_!#:(\3E")4ZH8/7-\4["PS&-XP6*8A_'V7&@/$0O M7N2_H#\J1,Q:'"\BNK&OTU$N+>N^C*-5,^7G@D3-57H\#!BOHO".GG]6Y_@V MG5-FXR>2"-!7V]08;C(!3/`%=$=`&`'E(P2TT<]`_6^N(4NF@D,HJ2>A/^S` MN=/?!'BZG(0/%-)1O#W;Q#']:>[=!GA.]^5WE/TO`CQI=S?&6%-!37"7\T+1 M$A7DTU MWA_'BY0\D)1@T:;7@(`Q3)L+:P)4R@TM*#NTSOC!;?GYAK)$)'R!ECE7Y!5L M9>AU8[!I<6SL?L1#K-?F6CM24;GQJP4=!+.5P5:@*IC^_A`Z7>/82^FGX>)IC<-$ M>%2JMC/&JY"U"6R9:0E%.6F$.6V;&#:26PKE%L(/@6NA`@[AK0!-?R@_BU:K M*)RE]+(RN_?H'$^29(-]`=9%K8T1KQ##!/><-&*TCQ"GCCAYU^"CT,(AB+1F MHS\HC1>+S6H3P'EJFM[C&!X98WQ/X4T>\(1]AV`_?X>748SGWM.I`&3-Z1C# MK[7H)L`L,441<$6+,MOLTXV>!Y3S"]>@VEICAR`VG.T>WR](2%)\1:6B]\:4 M3B2Y#?`X27":O(_%YUAE-_.7"TW!3+#*IH8B,B>//$;?-53JJJ+R4M%HDGK< M4ID(F6E1M%WNM3'?"NM8FI\[%YR@!FYZ$UCCP*DO]2![<-W(*_NK&!Z]'@VB M39@F-WB!R0.8R,$>)X>UK(N-#[Y2(,-O.Z./_N"MUE]GG_>X8):@$0JQ<\\B M.EJI^7YKSE-3N"5X\?(N>CCV,>%(HS\<`HS^ZN_G$3U!P-,R219>\!/VXDOZ MF\/OL:QE:SAIL#=!44X:<=H(B"-&W17D:"@@!XSV!`SQDENX*O#M^\A"0-GWMM\+#X)FQQR+8>CLO.,5PJY(4^*LF5 M^\S0&U.("M$0D\V5-=&IJL4OT=;AU>,ZW-PFS"THO8#7]$2YIH3MS=>'2A0C MK!?$$:?N'&15HZ_`3V\F^O1\>,Q.)!3BUW$4TA\7S/,,5L39/9T.G$S"A*UX)0C\Y%A$;O3F,9]^ARZOICS-T>3/]@"XG'\644-3[S!#TW/AL3/"(1U[E%H2N?EH@G/P+PGX MT":IA2^)C%!77Q(-X6U^228??[B8S3_-+XF&JC2_)-H3/3BV"TGUQ,_Y$L:VA*DUL:T]TCZYP@H?Y[\,8>P'Y)_:_BP*(2W_OD1!> MZZ?A#,Q,7/B8)/1/YQLP.O$(4CKRZ7+N/0E60&?LS!WS.E:$R6K:R8#N*/?, M;P3LI(3MEOQB'F+FS9QZ3_081']X_OFK%T?H\U='["=V;__\Q+4UU[7:*]YY MO0!P^/4+HN>R<4GI[^D0$WR.^?\5WRH+A#M;D\T'9^X@(W'@`)9V>-KVL5>+9\[BFG/B;+J(\N/^U:Z!KH!>)#[;>O/7M M/"ARK[)DI;1GBIQ/Y^,K-)[-+N8S^_Z!3224.P9JBCF<0Z#04VM0V]_[*/(? M21`(\%C\V1B1AXQ,,)G3KQI3H*R&);.(,HKJ:BUN:OTG(QC%)%`&D' MDX\HAEQY?=51O8OO4L;O47V^0]D`7&UBG%V,>:$@`R'V#P!4--QNOW69O[& M-J#)<<\$2H4#\^DNG$9\H%!VM&&(U!3.,%@JWK"C;HJI4"E[A:J$3-E>!9#Z\@0RQFBJJL@O93K+)&X?^/I6+7S?TSQ]P>@_/&<5#J_3)H!\)+#U#]*HN"T\;MTPF M_JV#U/F9LQ_[&WOVMKR1N*@BZ7'`AIZ&>QKJ5=?USTT#+-^>?04^1F%Q/N32 M9GF*9'X`XDYVWOB50ME(<,%?[+/T4LYE7='30^U[O.;L]/E6FJ33)3.PS*)` MG'%JOY6%-]!:MF;OG0ESJF+6,)10JJ[A1C#HZF.F1-E=A>]?T$TTW5Z2`,=G M]!A]%\7;@^D3M3(*VY>P-<$")XL87903=@4.BG&7(_65^NYOHX"<[Y,P26.> M.L!;X/$*HN0$.X:PN?'6H1+$*-4#I8UVQ(\0D$>) M!R]@(M;Z6(H.6DU(F)_"6@AL:NHG&5UX4F?F<+##L1_P3@2;QH&N!JF3]-EL MI(.<45MHJW*`;0WB(0W^>0JM:V\+YE%M>_]AOP[,_0+1K*1&6W.:Z%^G_]NM M;=]@$&E1/4YC)*ZM*&U-J"WX4JCU[=*J\'TX:&3)Q=6FIX/+WJ,J]P:9=KO. M\`>5OVIL`WM_MI++K\S(2@(_(.C*?(L&6I>HKZI2%YQ("_-Z9L*%HP1$Z7+*1INF:/F@<3UJ1G:T2T M$,_(^717Z8OO;O`:CC-V\-L$&**(<[1Q7[$]P,85S3[1<683Z6U/MO4/8WOP&H1+%R'91HN<:JI0#KQS5]29A"!0E\^@& MPY@)JZBP\QF;1W;RC'7"RB)V[2O`"/8[N>``$.>2L81*^;4X8O_2"K5P+AU, MEXH7+[NNH-??BKWP8@C-3?)L#^4R5`O#,O@"N`4;F%><*$*CNCG`E`#O8_2L_FNUY+ M,:6/Y;JR#I+CH3K>2IH'$0SZP^H-3CT28C]?0J5RCN=X219""&MT-$:VOG!F MB1PX%X0S-JXA25\-AP!K.DE]>E'LI[2FAX>+)TB9`;9S>:H9K:X6?"GT!;01 MN'"0S%Q=8&[H`4DWYM:C&L;/0E\S55>+IF`W M(S]"@8A&,1YPJ;/LJ61=>*FW$K!Q6GIN<)^E7IS*QH"\M)01*5IFAOI/8&@7 MH:1*!1\8AM!PG2&YXZ$I4(N>:Z9T0QBHSK*6>]EA6[MUEZUFV=^K8>R>W4DV M;FDQXWY]T'A`U(\X"/X21H_A#'M)1$_&\`:!XX-Y5;>W$+JF$,5"$!MP&/T" M+%#.`W$FKH!(6QO5T#:MF>D63&<4Q+$73$(?/_T%BZ,>#]M9`(^`M0709)01 M(XTH;?>P(AA\%2-2Q0_@B75%[^(3^J/(E[&FH3V/K`IS2UY90!J,P,9=Q<`U\S'55.2BUFLC^0ZJ:Q[""!92>I*\_!3AHX9_C5SEGI3+9* M"!4_)\DBB*!AWCM4?\//@BV[+'H<^,X]+J#BV)=1!`VF009@Z1C`_*,CAIM:&J^G-;6/4;H2F-M&<.EZU.=P[ONKO'%39@2R9;M(DI;-%PCOQ MO5_6R8810$,H&Q:!O7)`G!,JL7(%F\T44V,MT)ZN_KXJ5U%X1[_H*_C802SG M>;3RB,@E6=#8^*L@%\($84!Y!*01T#YR*LQ6;_2'6YG.'/2=,)>%@%S3[51\ MVMAK92GQ;(6M\?LM^U;6A_BXG_BTHH[ZY*2":>@/,S]BK+:-_(-#I#^^7'HF9 MU^('[,$3`HMG+'[Y':$G7'KBV$I-+LUH&*^25B*;+""@S:M_'Z$R3\AOG?\% M%7Q=0V4K=1T"UF"*!\#RNVU)S,L8_[K!X6([?B*BIR:=GO9PJQ;/!*TEVJ@@ MCGX&\L[Y)C50B1"1NE,V0'W='Z/X%WC&B198F+I/T-A>%=U:(4P`!@1')!RM M.4G7,"4?N+!8KD3]/<;A+Y=XD4Z7>9ZB&R^%_'JU40<"/#4B81ZQWT)@H]5&1CH43G= M,0.;&_(*CJX!WZ(&:\OMV43(`._]VJSO&@A@C1/Q6$S"P5&ZQD;>2_M)W7]_.7)*<54C!Z` MP=?(VZ3W4E+W[T[-T]F%2M!P M[V2>"!^QZ",K[6(C6;%2(,//+://P(5SXFZF\='114TZ8LW9&<"&*@;57A-[ M]E)+H,GI67YG;2NF^H75-237C51HO35&:K-(B!M\1R#&D"X1;U57S:FVF85H MAWK&%N(;=H014'8%#*J15P,89#H?H.P3O:`E>^5S6+K+7:4<*)$#=^I3T4VB M.2%[Q9L:"V]TT\BYCBC;$?!%.\9'B&?/UQ_HT#TH[D3OX5[XR\+QC?1YC9=;H*\=J?X@B'N M8N."H13(GCWO.>3E?\#Q%D5+7H../VQZ>:56^G=,'ER,7M=15,WM0W/J^O0[ M7E,E$UGID[TF%OR)JPS-?(=W]%P#2=U8J^[!(NT.'@-6B>]YYR5D(4!),QI= MQ7_)1;8=_74+Q)T[D[52C6;DE\YT#F(TYH*-"\NJVGY3\B M9\?"-1AJ:$-B]Y7/S@#)_*;+2Q)Z(=VI@^LH8:\HBFQ86EWM)?S3$-!H_RM2 M`$9+5'!".2O7T-=$+<+L@-H3U_[RF5?N!F,TL^I,0GHR7GD2?&EW,[J`-A', MZ/R6UUR')X?,1%=BY4P"Y*8Z*5]`F\]6G['3:UX[-)DN6;ZP+%V88%,3-K<0 M,2T7Q"Q8>KTKI!NRK&AK=5:T7D>@ET&JW4"&B?N6*Z,:\JT#K#X__/040H6B M9%?0+FQL;&PIJE%&*^3MRWVR?I)L[* MJ:]KG1YL?A@L#U3O4V%QO(,86!OKK&)N;0GE'MW>\_JH.X]CP;*L:VGNEBYF M;[+0"K*9OZ[-E60HLKR(60.Y!_&!%X^]XM.N@DO/YZC[**"Z2F#!I5NEV438 MP,OBOHT5)"V4])K%VTL2 M4/#6X*6^G04?-@%K"TYL!67$2;L$$>G8JVYL4KT/X,=V&<6S/?\C55D#G9[V M/-74XG7FFF8[M-?RF.21O;*!N;)Z6BA&Z$:G"\8!DM;P?.Y9+A-_&MZ`C''V MF*Q<;HW)V$MGTU!P.YF8]A(QN8;4MJH1YKAI-:F]>AP^NFG)[G!#SC< M8'%';]!46X<]=E4$\G.JBSY3BH:VH:T].Y MSTQ=@5=7(6K_[T:FI5I61G?^G"`"BJY@0CC4L@5)HE9+\6!74>A'X;O8"Q?W M^@%A@E[V(L+D8MD,">.<$&?E=D"87"G"B#"=R>HU),S?+-(?O1@B>[?ZU54U M.MH(#],4S@2".7D$94#B!V<`UUP+-1%@C>:HQSBP0I3ILEQY^@8'X&1R%B5I MLJM-7;A6J"K^&E(UCS:S,RSC5^'1NTHA<]=0;4E5E?@VFQ#H;SWD4>;3$#)O M\$Q_(N><^K;&V)6*8(+(YT"9Q]M"M"W94;=IUFLOOIY_6[M1#+&RI)HX7"\: M8!H^+^LN&\-W40!7^YW4NP>G<4P2^J>R;VSS/*TFG#K+VVIA^";KMY0:Y(ZE M!H$U\.)@$7RB"5TMJ%8WP:LU:`U2LTFPCJSF$+><*GP^G8^OT-5D_&YR-9E/ M+F8=E66R]VK41.`A5I%&VF\'LGN7PWGDI<;J6AJC6,+>*)X@*].UCF*60-OU M@"R)&@XQHYR&'MVRLOPH6O`1-#9WOI(*861[S3/=.`H:^<@KSD<:^A^RP*'" M\US2H8."AS8]S\^J)0.=\SE7:T!=.W#H8.F21./0;QS:H-W=)MRT!#4!7^E\ MA,8?S]%L/CW[RW?3J_.+FUD6!G'QW]]/YC\YC$@M)4GPV6`Z!W"XG(3K39I< M027M5[4/6#H][+E1BL6QXS%YA#B'(\1XH%>N`4]#$T('2=7,#%*$LEH?DPFH M5X=2UMEF*4H-(6WAK^#@?C5*#:U("E)JSUV?^=133(&10H4+`?CVFEC(IUYE M:!:HGMRS$B3(9U8GE-YCM.;Q8+P*#N?G&JCJ]%!-8R[2_,"E^]B]Y:9(-RH$ MCD;7;DKW"02TCM7;S?EE]X!6M( MT-C<]ULJA/D+_BU[P5^4:.=E(EV#F5P3%?]PC?D8XMW]G"3K+.G>=,G#@I3O M[W5]++[#2T0R?X\_OLI>LGW&Q0O`HNPQ)MT\R[<=39/G^9:#&O:57J(8\6N] M$GH#IL55QUE(N]A/C&LYPJ(V,Z[#X14Z^E#FQG4@L*):0%CY/B-H;^.)1BZ* MX4'9Z;+0RL'7/-3H3$2/MB02DA1?D0?LTRLBU3VAQUF^BU)9-ZL-E@T(F+NP-1;6 M!'24&UJP1XB,'[K=HN<;,'^!QSW)N=*O;<[6YM&BF\%*'3TMCW@0][[&6JMX M_;4$]"#%6$#2RR!Z3/2+L%2[V"R^(A3(S/)<*KK"W@49"]>PIZ,&29$5Q<3T MB"\\$X],?^BAZO02@*?7S!K_\BI.EU-L=<(R&-T,G,;D`5='-[A!E??QD+2TAJ6)B#*$I9RJHB1 M=04TTC%7$Y4*]=P5!#*;',^>^Q/V8O&=1MC4"!`J`6RX+&?YCH&ZD[<;E0[* M.-&;A?Z^9]P-5=_8(FYO_-52BF*TQP!Q!\_DRD$??H`T)Z#'`&#(DI+9#<^B M,(D"XO.R9:%_3:>=HMWC3YY%I;SB8)?HYRZQSL8\]+>C@9O`G*5`A9M`60#7 M,-^5XBI1O9U"9O@0>_`JN(QB3.Y"_EE9;.>Q%R9@@6"#9/\*^)"+,&]%,MJ. MF'46:&]'"49>W9P[6F3L4;KC"$E!83FFWA-FZ_+S$T1"Y`5!YJ[KW`>I6SWK M!M[;1-N0A6R$)J=*PPX*U]@`-\^*G(C*UM@TZIH-0".W0HZN*JLE"9U*& MC4=\W3@>\767\8BO^XA'?.T*L!IH0B<>L79FAH77:6-XG78)K],^X'7Z*<#K MM#F\:F=F`'B5Z[$4Y4GT<";K:@]P&@+:0EZ9U1$JF#F+0`W5"*&H/7G]NM2% ME/;VQGO\X*7TTND%(G^5^K96'.B$(IC`C-)#JYR@:X"2CKK..4ZA^?X@,P?O MP\+J-=NLUP&#M,*/0MG-&$BZ@AE=>(%'?6#9=Y7-!$U#UF'4]JUPR]YXRYY)+ M.E9F]YFNP?R97#SA>$$289F:)A3,LZDW%]=LMWY"MSC$2Y(B+TUC5B2GOL30"XJZ#$ M(39"G[\\.45K+T8/P.-KY!5UAN@?WQR=G)R@A$5G?HW"*/L1D22!Z,$H1I&[ M,:D2%]CNGOO4C;G^WDIQBD(`V&J?KNTC>KX6!^B461K M+@RBTJ#90;UG)A`JI1L'D1`+Z2\)A8(0!7KG!>?UQ-]M9ZD7IZ*CT;]55J>R MBU"5AG77!*-X*4ONP9!DE)6SV$_\G//,_KN;^!R^$:L'S M9*=ULEK#:WMX5^[V$E[`N.M,PI*.^61)-WI,OQWT')8^8ARR7R_!`,@^@,PC M?!$E3-(F`KQTY?/7"0K*I<8Z^NH,8&/4=^>3=K%G<>S(S2ZG#^OD7Z^LWMYM MB:Z\NV?RN[+*FHQ?:#UUR&FO1A2%_536PV*5,Z$X1O&@4`[`-2AIC%E5.:7'+D\K3MDJ"_,\/1T,V-P%;ER^ MK)C+KI>\R.GCF88*U(EIA9`:TW]A M=D6/.QC7UI.F,D0/DEI@ZS'ZMN:ASG+1#`*5<@(0V09)"&'?+?L>1$]OP4>+UR#EE03E;AG]6ST&)&9 M?Q`R5*M2#(G;F\=%JD0Q@51!/,]KZ]SG7CG\2L2AWE0,Y1=Q[<73F$4A^^S5 M/(>[EJN$L+-E[PF5D'8<*K))1'?1Y'_2`)(.':8 MPOGPWXK;7WNZ-GU#S89FY09);UN%(6.+1M5(.$57YEXXU'+^B1JUEN6_HC_1W^6_HO^!\GKT-_\'4$L#!!0````(`'I\ M9D=EVU5)A!0``'I2`0`5`!P`=71M9"TR,#$U,#DS,%]P&UL550)``,H M#SU6*`\]5G5X"P`!!"4.```$.0$``.U=6W/;.)9^[JF:_Z#-/'BGJAW'NG9K*T63D(0)!:@!4K;ZUR]`BA))$2`H4B)`^\47";?S M?0<'Y^#ZR]\?%VYK!0B%&'TZNWSYZJP%D(T=B&:?SB#%Y^_?O_MP?GGV]__^ M\Y]^^8_S\]:08,>W@=.Z7[=ZW<_M$?6A!UH43[T'BX"?6VUG92&>H(,72]\# MI'6-$%Y9'JN!_LS^L5_^S+Y;K@FO+M^U_GS#UO^?'B@F=ZO"?N2TQF%ZR.-Q=1PA=__M-//P6)/SY2F,CP M\"9*?GGQV^W-V)Z#A74.$?6X5&%&"C_2X/,;;`=R*539$J;@_YU'R<[Y1^>7 MK\_?7+Y\I$ZLH5/H)JKQ/6N^``['XH)C]^K#FU>QY+S`@DCL9=E@+ MX-MX:E:NMK-,5D$3#VHA4(]-%;+\&G%Q0NEBZ(/IL3,/WT MPO<6SGE4..?B+\IE7^RD6!)`6;+@\QOV0:):\.@!Y``GJIA+4+60L+O;9OMA,\;[+JFC?4X]8MA>5XUKWP/UTIISMHF@3XRI'@?UR MAE<7#H`O+C=]Z"_LH^]A]2,P@[Q6Y-U9"Y!JL#!9O(%Q/MLD MV5B+V%&1[,^`S#.AQF]27"R9T43>N3V'KA/EGA*\*`!@U`@LD:'E4]8:O.09 M+?>LA8D#2&CP3X)_),B$%9N!>^)KP_!.BI:-\^M3XSP$!&(F@].U/!G@R72& M(I\2-IN"-Z>BH,V:Y/!F]5UKE@%]\GO#($\)EPWUVU-!'3:[PYI#+/>:#:6/ M_P1KH5E/IS,,>H&PV12\.Q4%'9]P0?N0VI;[+V`1L([`$A./ M=<4QP]&G8KN4G=Q(.D2B"T*S5Z2$Z'P`FY.'E/O'+X^^R2KAXA2&L:' M4&`!$R<+K9,-"\-^-2[B:8UF(R&T@(^3Q=\38G%W>KQ>W&,W@X/D]X;AGA). M@/4VT/[E8D^P&_9!%0L:7R?M+[>][G6G?3,<#;I?.Y/Q]5VG,[@;#VZNN^U) MKWO5OFG?=7KC+[W>Y-"EC8*UG&B1HV"KRFC]U*+W@6+Y]'QF6B3 M=!_8?/R=>W*`Z]=@VH?(0C9D'153*%D>*92U5&<^7*PVI<"C.0*D$M74R0]A M@G=TD:A'6BXIR\4FA%"B))W6:&;V!#_2.LOA!'4L.F?#"__5^]V'*\ME[:5M MKV,1LF;CR*^6ZZ=G18OEK9E`J0;&&5-$0MS%6DRZ*6#U.#;)KUU';MHU9\$]'P`9, M.>]=<`>\C:`B@RK+8@I11%E`/AWW@ MS0%)"",`/R.A*11DR7BD9=2*'#X51Z]N^,6:(W3GJG0"L&>YM3H!0X*7@'CK MH6N%$PW,]UGR<5%LP*19#/77Y3!H-\Q\QMAY@&YZ]FKO:T/9V(FGW4C#Y(`> MN($KX%PS,-$,,IL,5NCETF M#^7.GK?.F9Y6SFZHC5>'YTB[$"MA5FVI09+!?/84%QU*;U\L/Y\E4N:Q(S+;!^ZW6V37QFT?>D$Y,C2&\:/R*QM5L(N,,>4.LY62F- MHB535.WF8I0[BWZ]1*)+\L&E68XA1K,)((LX&B(*LY*:ZC)DBGVD[?:'L]/= M*-/$>HSI812[,%*D_Q=06;Y<0WFO`-!C[?VO6DON,+*E)CDW6Z,XCL-Q MK*,#E8RC^0-HW<2HZIM@&&W4^%EX*J5YDR?%ITO*'P0IL^:[4;"@V;(M?EDI M:Z0!,VD7M;<>!86N&%F0N;\=:0C:0QI14 MQ&U^1K/(5`!"NUT8(^!9$`&G9Q$$T2R^2LD\,VA#D>NAD-$H]E2`T&X'QKZ( MRHYBW>RH*Y[D2FM3F\.0RPG`,/VI9[FI.< MR2JU/-:9;.+S&<^C1;`,Z`$)FNL$D<40D.#R)*6@5IBY=NMSZ$YF-6BT"X*3 M#0]OOVK[WAP3^`=PE+CAT"YPSFIP[TM>3 M5DB9=*03I6X*5?(QKL9=P05NE%7*TA3"%(:V[=[@6F<8QA/V\[9W-QGTV3># MVU[[KLM^#4>]+[V[\?6OO?#3X\TWJ#9`F]D'U0;7=8B*KPQM]3AG^D&4NJXY M:\L%=`16`/E`?#0ZG:KVTS]2Q!-3U&GYM)L?Z&#*;!_?IT;'V!4/M\E4YC"P M)Y]V47YPHG=(\%2XO!9/43/R`G5)'#./R].@]9C!$A"+W]7<>UP"1$'>97CB M].;T'HG,VLV^C('K\O.7`+$V\QVW;6Q3QT&Y(&C%<&2;\WK@N&SI='%P9(N=/GL$[QB\PP@GY90;S9Q,!KDI.=)KM]2PT$^ MD[F#$6NTS]J]45.,-ML\PW03ZQ'06X@P"6XK]P`CPPN.%,5+"3?&W`)OCIW8 M19S2B8#3M*!N`Z'4-Y)WKIR0G@99H2T>&VROF.\I#FM%J2Z`%_D(E2MTON)6J0=THV@8;+;!>613:`MZRTVI!H5(7$LBJW?)DNIU= MZ/J><'E2E-I<7K;R:KT`&T[UE.5DO*E:&.2P6 MQ$:[.XT$[=\HH^H"=-%2C.=7C(]V%U'(CKK=`6\P98Y`^,X5^YP`BX(N"'_G M3;^7+]@STA%J),#,X.J>E!:6)T>[198,*7-4299#4VVHJE.E]NF)@6OF M$4+%[6HG.EUX4&M,V_JGPYE$H_<[[?&7_LW@V_&&1&FMV@Q]TE;6?NR>/RC:=_%# MWB9,:9:Z[IH&'F_+D.`59`Q>K;]2_D+(=HM*FT7+J[!/R84[H"!]CML(&4S< M57T`5-H-7P:MO1;E)W\!MLY[Y[9N#9W@$;`QLF'PT.G.)YK@:GKB4:HR3!>. M`[=VV\R[@'%A0]D39HDD=3^$>L1.D+P;.0Z+=C9X!P,+@Q1>H1.G?R)\2@#3 MSM#OPI'\?8_9:9\(J0*@RN]DU^A1P0`BRD1A>MO%_KTW]=WHI2"Q_R7.4K-J M2'4[Y8I)Y-;.(._DZD*ZW)RX'TRECTO(\SRY/IP)G'BKNX%].7H/H-B^XKQ< M3T11M?;RFHMG)FL\`IOW%! MHT$^`S"^#K635W*$+2]CPW1A'QAQ+-X(3>`Q#V*UB5^ODN=I&/$.!H5M>_+ M.B1@:4$G\F(WSFL;A8^C2./$`PMKF+*H`=BH>%$\>LH?(,W/US#=V(.E0;%@ MIK2IAZB+Z$$Z:_-480\<<2QHG#94&5:?8/%7/^T2=YYC+?XVZBRW^@Z6TIM\ M3-6=(A"5CW=TUXQPF:>";6"R@@R;[SH$*OVNX+#6&_O8MG_W(0%,'*;BWGKH M6HC?%\-OB`DN>Q,M4ZH78!B_1:`I[YMH%+#L";[_*KR:*NSE,UT#]H$07SQA M(/'J%JVTT:];%91U_#"+_Q2\QX((X_ M^<&:#IC\N<\EY^/[)_*FD(W&H2"@]^`'X7L/;)VH1E3LJ"E@Z#R]&!;)*,-;'8`HH,71X>;J7L0N[N(2. M;^IF7Z*ZAX4SC0IX>],IL%G'B#R0$5/-`>)(,(>1_^(S?RO+E9SH*52$8::@ M&#P"O:CS'=;,EF9?]26@MU`1AM%;#!X!O8[[,E;S,;2,B:F3M9U*R6 MMQ&JL`>(0`>*S()O=&`9:!EK)O&:K0G?+QNI"TPLD3:\/U0;>JCV_7O1>QI# M"XJB\'0JP]C=$U+`8HTSF]$C)E(28DF,8R`NGF!+R7;R\8@W5'4AM5U,_?#9 M`Q8B#&.5''H!E;S0$]TO)6]$3?-_VS9-F'17K*8?.:MHLAQUW85'9A;:7,70 MP8AB%SK6YG;E.,:Q]\RWW8-FR".0O/)J:C81"MPG;L*K'.6<`_@G,3)WX&&S M\9LOP!",V)]VV&;N;@01)MUN#@_20"8;LSNTO#$J4_G)C5:9QCX;MQ+3@@?# MGF?0*BG:+"-6#9HZ&*[8N;?RABA>V,D-2[SR9T-1(D`)85RK>S32+&9U;+GT MU:T.I`[OG*2K!RO.>]=3E._U@G)/;@`$[7BV!14($6P8VV(Z`BY?Y^Q@ZM'= MI2?;W:@YYJ)LJ699E-(8ZN`EQ#=`5!"OQ$L[?0`2K[WN?F6R<0#WGKJ/($IM M6&<6R6RV9_#-(L1"WGK$*B&K"GIXNL"3=_)T`Y[[>9F-](YO>Q&BZEU>(:-9 MO5\%"1U&Z]AUIM7$]%%AM<3T4>7/7;C:6YSSNF].)K.Z;AX"9H_??0N28.?" M+;#X_Q5U_>QB3VX$LIOQ;`X.%F(+:'A(=`.K,V`QJ>T3LGFT/-=`%"[&+)-1 M'"4=QOZQ?T_![SZKH+>JQ@KLE7CZB;UT"Y[[_N$G*U-8YG5R<7JS>K-$;AVZ M;8D%14G6(7:AO0Y^5K*^=Y)6FK0C05VJFF+WH!&JYDJ46K\M"S%PUWD6K'`Q M=9]JDG.FN`U!@)`.MBZV4#^VY\#Q73"8;A=>PT=TO4EP"W.E6Q)R*ZMSRT)N MX^KI@T'E6_T9^TM&@,(;V+G9ZO)^Y"CG.D.JV6LV(:JL)1PD96ATL2&;69SV MRH(N;V(?D['E@MV[R57:$-7*ZIPBS6WUF%$T<56:YD55&'@?:T8I!U M<==R`YTN\-A`M_H;)#_ZN#K8!S:4JF=@H=E)R:O?>][:A M(^OAUF*^-K3<7#X2:8VB(RFE^-FONME@_3B/!)[$*.P#F5&I83>Q!G(%E!['KIX84&DR,0F<;WY73X M1?]7%OIQUP[^Y';[%BSN`4GAK9A)<]Q51:\P?%;`G[7:P>B*6,B>JQ,@R&4: M`R+AM8N9M_:5>4W@FOTI&APR$FH_-&0)I]T<$M>I:\0\#)^WM&_9H+W@>]0D M)X,SD^O"QIXBI4\$9PNK0^2BM#FDTG47Y=KTW"CS9(*@[/%.#,QG@BG]B@BP M7/@'<*+S=&W;]A=^<).%B]P=PAFC8G5EZQQ&58QB9=MF=+F3.@>;T089CHKX M5?!"9>BL+0>BHMV0OVW_%!.JHO&7>=2J%V04OP7PTI1%;+B9;6GY"C4_SS!Z5P%\9L%[ZIY MLL#8?;:5A3?';%PC=MH^F>#I>07)Z!6DK7)?K6/:WR?!^7![+5E04LFIR[25 M,W7-V`%7#5S*LMLDD65@J`O>W&EVQ>AL'D5EZ%/YU10U]S^*89* M7ZM[C9:^1P-9+]6,;48.\VG,@D'?_AEK[>O"I+UN(FFOM=V!D-7:-X5)>]-$ MTM[(23MH@O)YVTB%VT9J[#;\/59OIV2[J2H!$>+TNO"QITJ)]\?%XAZ\!?8___,?Y_]R'#04W`\]XJ/)$K5;EXUK&5)%D.13=8<%.40-_Q8S M3=#D\T6HB$`=QO@M5J!!'L*+5SZ$L<52T-F-0F^:OZ*C2N6=-SY#@:DO1NR!PCL(+) M&N.,A?-ZZ4:I14'#J1H,K MTH"R;WE@JF=G9ZX934A]0C=%2N*59_S6A8$<$%,:;,@-%;Z9$U_/HZ8^K9P= M@^,5%C.B^GA.Y`)[9`>.2'H&=MK(8U%(&4`E9`( M'@#;5F!ZV`46"28:1-VUXD0$%EY&2B8.0`A?$*$HD:OY/7!?QB2?3/[&L0L)#@9[3%P\&^M@"+%P:O'&Y:QAAL0/KAXW5G0UY>\8BP45]\ M;5'I!5R&@O3)7,@4+#^PT#!X]$P]D`WF-V\PFQ'986D:RCP*4R8MK$,> M4&]I_@7\!XCZ]8._0&\T6_%TK1/F?056FK<5Y*`U'G@!N6@M&&U*1IC!\AK! M0I1M$B;(:G89ARC"A]XD"'\]=Q]B2T,.)?$'[+UY?EC"8LZ89!O79I78C>=! M\.8PQ9^2`'SYH.2*R"%>XHG.S)S@28_;G%S-.EFSHIBWF/V\V;_`5'S"04AZ M!.MW$[NZ*?/#@`RFJ^&&E,1D:Y?B"0VH+E4Q"V"])EXH(#-F'["D`6TT#/%72E(QR0D9Y(,[\MHF`H-Y3VXK<$Q]%Q)CA2HFMH M)=R9;@_YHT.VT M&N-V"YY;[?ZHW1J-X;77[H\'%\W&Z.JB._B\=O8SY5B<7C$-P0B<8/(>GK4N M%"M#B3;83?>;9936B%8JT4HG&EP@K15IM44@;,MVIKB`G%F7^^3CL@EU$YZV MKQO[L-L6@G_GYGHL>;/XKZ0?HEA^4=!W=?$C+K1F9G:M3G$6,Y\W\R/%O6_0 MV\ARC#"4EE8LC4];&C\TNHU^LSVZ:K?'0ZSK MS@U1%/#NLRYN%V)+O>,G+XJQ/F04PHXWK;+P?V[2?L9"8*:6UV"RN,W=^3XD ML:UL1YG$3+A1S%ZX89\T3#64,#+HM1M]Z#9[P^OV%71_G4_MZ.N3,_1)\FW) M>_KDY-WH8R.U"-"@#3C)0)';KQ]4KQ!'UM`Y^2&A4X3*DS=&CQR#[,QOZ^PJ MS]L:%LP^[[-O?7=EM3<*[9QUU%;O?'WR.;DG[UU1GJQ(G?\U)>E%=]M__ M[[[QM]:,[+JP;<=?."?E'.Z%.@^2_R$#VTQ1M>PPJ*WSAP[:A=K6P47',C%W M^E%G620*I605GLI+(U-K!M-ARN2\',HCL_DF>^8<%34HBVD9A4]>^!F:WCS!YL;ORJI^@- MG_]GAJ?^9<%:$H]>YH\)A5@KGMVVW3 MGZ&Q^>`TN[]:L:.(_^_CB7,W=3D`7C9N#IS3^8(+A:(K)UWNF1'+-03]YB1W M$1S]R:D>.*L146('X%B MO09D@_*01S]L41[?SD%X(I7`GJJ7E`@)3"8-S,%L\FYN,Y3,-9T:4,+&H0/K MK$XS@`+E`S;\H09R*7BX2`@ID)10]+P`5W-_;,3XH3"H2[J4E:8T^&H[AVC$ MT"(/UTN[T6Z:EV].=+NLYO,YINQ%[?E]V(-0P`RV7!+V[^Q;OV$>=2?9(_,) M$8DUNU#^1+9T.?,Y^R"@AMT\8LPVTEVLB7#-.8-66RQ?Q)QH;((#77[K)4\0 MGZJUE=#=:SR#Z1C?$WG!1?O>,_OEP=0T2/F1"8(#^B?Q+R&6NO"EX4'*Z<67^`$+UAU;,ALO*%#/U[D;53=X M_#]02P$"'@,4````"`!Z?&9'W=-*`8HB``!WD0$`$0`8```````!````I($` M````=71M9"TR,#$U,#DS,"YX;6Q55`4``R@//59U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`!Z?&9'RO:847<*```'B```%0`8```````!````I('5(@`` M=71M9"TR,#$U,#DS,%]C86PN>&UL550%``,H#SU6=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`>GQF1YI5)]':!@``-DP``!4`&````````0```*2!FRT` M`'5T;60M,C`Q-3`Y,S!?9&5F+GAM;%54!0`#*`\]5G5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`'I\9D>-&S.,:R(``$>Q`0`5`!@```````$```"D@<0T M``!U=&UD+3(P,34P.3,P7VQA8BYX;6Q55`4``R@//59U>`L``00E#@``!#D! M``!02P$"'@,4````"`!Z?&9'9=M52804``!Z4@$`%0`8```````!````I(%^ M5P``=71M9"TR,#$U,#DS,%]P&UL550%``,H#SU6=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`>GQF1]T1^L-J!P``SSH``!$`&````````0```*2! M46P``'5T;60M,C`Q-3`Y,S`N>'-D550%``,H#SU6=7@+``$$)0X```0Y`0`` 64$L%!@`````&``8`&@(```9T```````` ` end XML 17 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Current assets:

Cash $ 21,622 $ 19,274

Investments, available-for-sale 53 58

Accounts & other receivables - net 5,493 4,703

Inventories 4,449 4,872

Other current assets 689 768

Total current assets 32,306 29,675

Property and equipment - net 7,568 8,236

Goodwill 14,904 15,145

Other intangible assets 38,594 39,675

Other intangible assets - accumulated amortization (13,217) (11,655)

Other intangible assets - net 25,377 28,020

TOTAL ASSETS 80,155 81,076

Current liabilities:

Accounts payable 922 929

Accrued expenses 4,819 4,148

Current portion of notes payable 0 3,894

Total current liabilities 5,741 8,971

Notes payable 0 973

Deferred tax liability - intangible assets 5,039 5,581

Deferred income taxes 1,022 995

TOTAL LIABILITIES $ 11,802 $ 16,520

Stockholders' equity:

Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding

Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2015, 3,750 shares and December 31, 2014, 3,748 shares $ 37 $ 37

Accumulated other comprehensive income (loss) (4,948) (3,234)

Additional paid-in capital 2,639 2,890

Retained earnings 70,625 64,863

Total stockholders' equity 68,353 64,556

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 80,155 $ 81,076

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax of increase (decrease) in accumulated in equity from transactions and other events and circumstances from non-owner sources. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).
+ References
No definition available.
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

+ Details

Name: us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Trading Securities

-URI http://asc.fasb.org/extlink&oid=6526789

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 35

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Available-for-Sale Securities

-URI http://asc.fasb.org/extlink&oid=6505594

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph a, f, g

-Article 7

+ Details

Name: us-gaap_InvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income $ 8,633 $ 8,378

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation 461 474

Amortization 1,898 2,064

(Gain) loss on investments 0 0

Provision for (recovery of) losses on accounts receivable (9) (26)

(Gain)/Loss on disposal of assets 1 4

Deferred income taxes (359) (414)

Stock-based compensation expense 66 49

Changes in operating assets and liabilities:

Accounts receivable (791) (291)

Accrued interest and other receivables (83) (50)

Inventories 151 (99)

Prepaid expenses and other current assets 76 22

Accounts payable 31 258

Accrued expenses (180) 489

Total adjustments 1,262 2,480

Net cash provided by operating activities 9,895 10,858

CASH FLOWS FROM INVESTING ACTIVITIES:

Capital expenditures for property and equipment (151) (953)

Capital expenditures for intangible assets (55) 0

Net cash provided by (used in) investing activities (206) (953)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of common stock - options 298 361

Common stock purchased and retired (683) (1,017)

Payment of taxes for exchange of stock options (42) 0

Tax benefit attributable to exercise of stock options 110 139

Repayment of notes payable (4,778) (3,052)

Payment of dividends (1,914) (1,874)

Net cash provided by (used in) financing activities (7,009) (5,443)

Effect of exchange rate changes on cash (332) (609)

Net increase in cash and cash equivalents 2,348 3,853

Cash at beginning of period 19,274 14,395

Cash at end of period 21,622 18,248

Cash paid during the period for income taxes 4,030 2,492

Cash paid during the period for interest $ 65 $ 239

X

- Definition
This element represents the total of the cash outflow during the period for taxes related to exchanges of stock options.
+ References
No definition available.
+ Details

Name: fil_PaymentOfTaxesForExchangeOfStockOptions

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11283-113907

+ Details

Name: us-gaap_DeferredTaxExpenseFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

Name: us-gaap_GainLossOnDispositionOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (c)-(e)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(c),9(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_GainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Notes Payable (Details)
$ in Thousands

Sep. 30, 2015

USD ($)

JP Morgan Chase Bank NA (Chase) Note

Debt Instrument, Face Amount $ 14,000

JP Morgan Chase London Branch Note

Debt Instrument, Face Amount $ 12,934

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=fil_JPMorganChaseBankNAChaseNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=fil_JPMorganChaseLondonBranchNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)
$ in Thousands

Sep. 30, 2015

USD ($)

Fair Value, Inputs, Level 1

Equities $ 53

Fair Value, Inputs, Level 2

Equities 0

Fair Value, Inputs, Level 3

Equities 0

Fair Value, Measurements, Recurring

Equities $ 53

X

- Definition
Fair value of the entity's equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_EquityFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 22 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Basis of Presentation
9 Months Ended

Sep. 30, 2015

Notes

Basis of Presentation
(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2014. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares
shares in Thousands

Sep. 30, 2015

Dec. 31, 2014

Statement of Financial Position

Preferred Stock, Par Value Per Share $ 0.01 $ 0.01

Preferred Stock, Shares Authorized 5,000 5,000

Preferred Stock, Shares Issued

Preferred Stock, Shares Outstanding

Common Stock, Par Value Per Share $ 0.01 $ 0.01

Common Stock, Shares Authorized 50,000 50,000

Common Stock, Shares Issued 3,750 3,748

Common Stock, Shares Outstanding 3,750 3,748

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventories: Schedule of Inventory, Current (Tables)
9 Months Ended

Sep. 30, 2015

Tables/Schedules

Schedule of Inventory, Current

September 30, 2015

December 31, 2014

Finished goods

$

1,424

$

1,847

Work-in-process

1,212

1,103

Raw materials

1,813

1,922

Total

$

4,449

$

4,872

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document and Entity Information - USD ($)
9 Months Ended

Sep. 30, 2015

Nov. 05, 2015

Jun. 30, 2015

Document and Entity Information:

Entity Registrant Name UTAH MEDICAL PRODUCTS INC

Document Type 10-Q

Document Period End Date Sep. 30, 2015

Amendment Flag false

Entity Central Index Key 0000706698

Current Fiscal Year End Date --12-31

Entity Common Stock, Shares Outstanding 3,750,300

Entity Public Float $ 199,695,980

Entity Filer Category Accelerated Filer

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer No

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

Trading Symbol utmd

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: fil_DocumentAndEntityInformationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Investments: Available-for-sale Securities (Tables)
9 Months Ended

Sep. 30, 2015

Tables/Schedules

Available-for-sale Securities

3Q 2015

3Q 2014

Balance, beginning of period

$

10

$

5

Realized loss from securities included in beginning balance

~

~

Gross unrealized holding gains (losses), in equity securities

(6)

5

Deferred income taxes on unrealized holding (gain) loss

3

(2)

Balance, end of period

$

7

$

8

X

- Definition
Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Income Statement

Sales, net $ 9,945 $ 10,717 $ 30,575 $ 31,035

Cost of goods sold 3,866 4,521 12,285 12,440

Gross profit 6,079 6,196 18,290 18,595

Operating expense:

Selling, general and administrative 1,969 2,079 6,039 6,336

Research and development 110 115 406 352

Total operating expense 2,079 2,194 6,445 6,688

Operating income 4,000 4,002 11,845 11,907

Other income (expense) 127 (107) (126) (300)

Income before provision for income taxes 4,127 3,895 11,719 11,607

Provision for income taxes 1,080 1,073 3,086 3,229

Net income $ 3,047 $ 2,822 $ 8,633 $ 8,378

Earnings per common share (basic) $ 0.81 $ 0.75 $ 2.30 $ 2.24

Earnings per common share (diluted) $ 0.81 $ 0.75 $ 2.29 $ 2.22

Shares outstanding (basic) 3,753 3,741 3,753 3,747

Shares outstanding (diluted) 3,768 3,764 3,772 3,774

Other comprehensive income (loss):

Foreign currency translation net of taxes of $0 in all periods $ (1,536) $ (2,569) $ (1,711) $ (1,459)

Unrealized gain (loss) on investments net of taxes of ($2), $2, ($2) and $0 (4) 3 (3) 0

Total comprehensive income $ 1,507 $ 256 $ 6,919 $ 6,919

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34747878&loc=d3e3636-108311

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Warranty Reserve
9 Months Ended

Sep. 30, 2015

Notes

Warranty Reserve
(6) Warranty Reserve. The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.”

UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2014 or September 30, 2015.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

+ Details

Name: us-gaap_ProductWarrantyDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Notes Payable
9 Months Ended

Sep. 30, 2015

Notes

Notes Payable
(5) Notes Payable. In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. and a $12,934 loan from JP Morgan Chase, London Branch to help finance UTMD’s purchase of Femcare. The notes were fully paid off in February 2015.

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Investments: Available-for-sale Securities (Details) - USD ($)
$ in Thousands
3 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Details

Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments $ 10 $ 5

Realized loss from securities included in beginning balance

Available-for-sale Securities, Gross Unrealized Gain (Loss) $ (6) $ 5

Deferred income taxes on unrealized holding (gain) loss 3 (2)

Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments $ 7 $ 8

X

- Definition
Net amount of accumulated unrealized gains (losses) on investments in available-for-sale securities impacting investments. Represents the difference between the fair value and cost of investments in available-for-sale securities.
+ References
No definition available.
+ Details

Name: fil_AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedlnlnvestments

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This item represents the tax effects occurring during the period which are related to the net unrealized gain (loss) resulting from changes in the fair [carrying] value during the period of available-for-sale securities. Such tax affects would have been charged or credited directly to other comprehensive income or to related components of shareholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 20

-Section 45

-Paragraph 11

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=18498875&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrealized gain (loss) on investments in debt and equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)
9 Months Ended

Sep. 30, 2015

Tables/Schedules

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

Fair Value Measurements Using

Description

Total Fair Value

at 9/30/2015

Quoted Prices

in Active Markets

for Identical Assets

(Level 1)

Significant Other

Observable Inputs

(Level 2)

Significant

Unobservable Inputs

(Level 3 )

Equities

$

53

$

53

$

0

$

0

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events
9 Months Ended

Sep. 30, 2015

Notes

Subsequent Events
(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Investments
9 Months Ended

Sep. 30, 2015

Notes

Investments
(7) Investments. Changes in the unrealized holding gain/loss on investment securities available-for-sale and reported as a separate component of accumulated other comprehensive income are as follows:

3Q 2015

3Q 2014

Balance, beginning of period

$

10

$

5

Realized loss from securities included in beginning balance

~

~

Gross unrealized holding gains (losses), in equity securities

(6)

5

Deferred income taxes on unrealized holding (gain) loss

3

(2)

Balance, end of period

$

7

$

8

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the realized and unrealized gains and losses reported in the statement of income which have resulted from the sale and holding of marketable securities, respectively, as well as the sale or disposal of cost method investments. Such amounts would include realized gains and losses on the sale or disposal of trading, available-for-sale, and held-to-maturity securities, unrealized gains and losses on trading securities, unrealized gains and losses on available-for-sale and held-to-maturity securities transferred to the trading securities category, realized gains and losses on the sale or disposal of cost method investments, and losses recognized for other than temporary impairments (OTTI) of such investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (c)-(e)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.M)

-URI http://asc.fasb.org/extlink&oid=27011274&loc=d3e87990-122713

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section M

+ Details

Name: us-gaap_GainLossOnInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements
9 Months Ended

Sep. 30, 2015

Notes

Fair Value Measurements
(8) Fair Value Measurements. The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets. The following table provides financial assets carried at fair value measured as of September 30, 2015:

Fair Value Measurements Using

Description

Total Fair Value

at 9/30/2015

Quoted Prices

in Active Markets

for Identical Assets

(Level 1)

Significant Other

Observable Inputs

(Level 2)

Significant

Unobservable Inputs

(Level 3 )

Equities

$

53

$

53

$

0

$

0

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)
9 Months Ended

Sep. 30, 2015

Policies

New Accounting Pronouncements, Policy
In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-Based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Details

Allocated Share-based Compensation Expense $ 22 $ 25 $ 66 $ 49

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Income Statement

Foreign currency translation tax adjustment $ 0 $ 0 $ 0 $ 0

Unrealized gain (loss) on investments tax adjustment $ (2) $ 2 $ (2) $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e,f)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 38 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-Based Compensation
9 Months Ended

Sep. 30, 2015

Notes

Stock-Based Compensation
(4) Stock-Based Compensation. At September 30, 2015, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended September 30, 2015 and 2014, the Company recognized $22 and $25, respectively, in stock-based compensation cost. In the nine months ended September 30, 2015 and 2014, the Company recognized $66 and $49, respectively, in stock based compensation cost.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 17 122 1 false 6 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.utahmed.com/20150930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Sheet http://www.utahmed.com/20150930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.utahmed.com/20150930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 3 false false R4.htm 000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME Sheet http://www.utahmed.com/20150930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEANDCOMPREHENSIVEINCOME UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME (Parenthetical) Sheet http://www.utahmed.com/20150930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEANDCOMPREHENSIVEINCOMEParenthetical UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME (Parenthetical) Statements 5 false false R6.htm 000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Sheet http://www.utahmed.com/20150930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW Statements 6 false false R7.htm 000070 - Disclosure - Basis of Presentation Sheet http://www.utahmed.com/20150930/role/idr_DisclosureBasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 000080 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles Sheet http://www.utahmed.com/20150930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples New Accounting Pronouncements and Changes in Accounting Principles Notes 8 false false R9.htm 000090 - Disclosure - Inventories Sheet http://www.utahmed.com/20150930/role/idr_DisclosureInventories Inventories Notes 9 false false R10.htm 000100 - Disclosure - Stock-Based Compensation Sheet http://www.utahmed.com/20150930/role/idr_DisclosureStockBasedCompensation Stock-Based Compensation Notes 10 false false R11.htm 000110 - Disclosure - Notes Payable Notes http://www.utahmed.com/20150930/role/idr_DisclosureNotesPayable Notes Payable Notes 11 false false R12.htm 000120 - Disclosure - Warranty Reserve Sheet http://www.utahmed.com/20150930/role/idr_DisclosureWarrantyReserve Warranty Reserve Notes 12 false false R13.htm 000130 - Disclosure - Investments Sheet http://www.utahmed.com/20150930/role/idr_DisclosureInvestments Investments Notes 13 false false R14.htm 000140 - Disclosure - Fair Value Measurements Sheet http://www.utahmed.com/20150930/role/idr_DisclosureFairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 000150 - Disclosure - Subsequent Events Sheet http://www.utahmed.com/20150930/role/idr_DisclosureSubsequentEvents Subsequent Events Notes 15 false false R16.htm 000160 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Sheet http://www.utahmed.com/20150930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies) Policies http://www.utahmed.com/20150930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples 16 false false R17.htm 000170 - Disclosure - Inventories: Schedule of Inventory, Current (Tables) Sheet http://www.utahmed.com/20150930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables Inventories: Schedule of Inventory, Current (Tables) Tables 17 false false R18.htm 000180 - Disclosure - Investments: Available-for-sale Securities (Tables) Sheet http://www.utahmed.com/20150930/role/idr_DisclosureInvestmentsAvailableForSaleSecuritiesTables Investments: Available-for-sale Securities (Tables) Tables 18 false false R19.htm 000190 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Sheet http://www.utahmed.com/20150930/role/idr_DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables) Tables 19 false false R20.htm 000200 - Disclosure - Inventories: Schedule of Inventory, Current (Details) Sheet http://www.utahmed.com/20150930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails Inventories: Schedule of Inventory, Current (Details) Details http://www.utahmed.com/20150930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables 20 false false R21.htm 000210 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.utahmed.com/20150930/role/idr_DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.utahmed.com/20150930/role/idr_DisclosureStockBasedCompensation 21 false false R22.htm 000220 - Disclosure - Notes Payable (Details) Notes http://www.utahmed.com/20150930/role/idr_DisclosureNotesPayableDetails Notes Payable (Details) Details http://www.utahmed.com/20150930/role/idr_DisclosureNotesPayable 22 false false R23.htm 000230 - Disclosure - Investments: Available-for-sale Securities (Details) Sheet http://www.utahmed.com/20150930/role/idr_DisclosureInvestmentsAvailableForSaleSecuritiesDetails Investments: Available-for-sale Securities (Details) Details http://www.utahmed.com/20150930/role/idr_DisclosureInvestmentsAvailableForSaleSecuritiesTables 23 false false R24.htm 000240 - Disclosure - Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.utahmed.com/20150930/role/idr_DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details http://www.utahmed.com/20150930/role/idr_DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTables 24 false false All Reports Book All Reports In ''UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. utmd-20150930.xml utmd-20150930_cal.xml utmd-20150930_def.xml utmd-20150930_lab.xml utmd-20150930_pre.xml utmd-20150930.xsd true true XML 40 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventories: Schedule of Inventory, Current (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Details

Finished goods $ 1,424 $ 1,847

Work-in-process 1,212 1,103

Raw materials 1,813 1,922

Total $ 4,449 $ 4,872

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 21,622	$ 19,274
Investments, available-for-sale	53	58
Accounts & other receivables - net	5,493	4,703
Inventories	4,449	4,872
Other current assets	689	768
Total current assets	32,306	29,675
Property and equipment - net	7,568	8,236
Goodwill	14,904	15,145
Other intangible assets	38,594	39,675
Other intangible assets - accumulated amortization	(13,217)	(11,655)
Other intangible assets - net	25,377	28,020
TOTAL ASSETS	80,155	81,076
Current liabilities:
Accounts payable	922	929
Accrued expenses	4,819	4,148
Current portion of notes payable	0	3,894
Total current liabilities	5,741	8,971
Notes payable	0	973
Deferred tax liability - intangible assets	5,039	5,581
Deferred income taxes	1,022	995
TOTAL LIABILITIES	$ 11,802	$ 16,520
Stockholders' equity:
Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding
Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2015, 3,750 shares and December 31, 2014, 3,748 shares	$ 37	$ 37
Accumulated other comprehensive income (loss)	(4,948)	(3,234)
Additional paid-in capital	2,639	2,890
Retained earnings	70,625	64,863
Total stockholders' equity	68,353	64,556
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 80,155	$ 81,076

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 8,633	$ 8,378
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	461	474
Amortization	1,898	2,064
(Gain) loss on investments	0	0
Provision for (recovery of) losses on accounts receivable	(9)	(26)
(Gain)/Loss on disposal of assets	1	4
Deferred income taxes	(359)	(414)
Stock-based compensation expense	66	49
Changes in operating assets and liabilities:
Accounts receivable	(791)	(291)
Accrued interest and other receivables	(83)	(50)
Inventories	151	(99)
Prepaid expenses and other current assets	76	22
Accounts payable	31	258
Accrued expenses	(180)	489
Total adjustments	1,262	2,480
Net cash provided by operating activities	9,895	10,858
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for property and equipment	(151)	(953)
Capital expenditures for intangible assets	(55)	0
Net cash provided by (used in) investing activities	(206)	(953)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options	298	361
Common stock purchased and retired	(683)	(1,017)
Payment of taxes for exchange of stock options	(42)	0
Tax benefit attributable to exercise of stock options	110	139
Repayment of notes payable	(4,778)	(3,052)
Payment of dividends	(1,914)	(1,874)
Net cash provided by (used in) financing activities	(7,009)	(5,443)
Effect of exchange rate changes on cash	(332)	(609)
Net increase in cash and cash equivalents	2,348	3,853
Cash at beginning of period	19,274	14,395
Cash at end of period	21,622	18,248
Cash paid during the period for income taxes	4,030	2,492
Cash paid during the period for interest	$ 65	$ 239

Notes Payable (Details) $ in Thousands	Sep. 30, 2015 USD ($)
JP Morgan Chase Bank NA (Chase) Note
Debt Instrument, Face Amount	$ 14,000
JP Morgan Chase London Branch Note
Debt Instrument, Face Amount	$ 12,934

Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) $ in Thousands	Sep. 30, 2015 USD ($)
Fair Value, Inputs, Level 1
Equities	$ 53
Fair Value, Inputs, Level 2
Equities	0
Fair Value, Inputs, Level 3
Equities	0
Fair Value, Measurements, Recurring
Equities	$ 53

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2015
Notes
Basis of Presentation	(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2014. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position
Preferred Stock, Par Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	5,000	5,000
Preferred Stock, Shares Issued
Preferred Stock, Shares Outstanding
Common Stock, Par Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	50,000	50,000
Common Stock, Shares Issued	3,750	3,748
Common Stock, Shares Outstanding	3,750	3,748

Document and Entity Information - USD ($)	9 Months Ended
Document and Entity Information - USD ($)	Sep. 30, 2015	Nov. 05, 2015	Jun. 30, 2015
Document and Entity Information:
Entity Registrant Name	UTAH MEDICAL PRODUCTS INC
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Entity Central Index Key	0000706698
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		3,750,300
Entity Public Float			$ 199,695,980
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	utmd

Notes Payable	9 Months Ended
Notes Payable	Sep. 30, 2015
Notes
Notes Payable	(5) Notes Payable. In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. and a $12,934 loan from JP Morgan Chase, London Branch to help finance UTMD’s purchase of Femcare. The notes were fully paid off in February 2015.

Investments: Available-for-sale Securities (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments	$ 10	$ 5
Realized loss from securities included in beginning balance
Available-for-sale Securities, Gross Unrealized Gain (Loss)	$ (6)	$ 5
Deferred income taxes on unrealized holding (gain) loss	3	(2)
Available For Sale Securities Gross Unrealized Gain Loss Accumulated ln lnvestments	$ 7	$ 8

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Notes
Subsequent Events	(9) Subsequent Events. UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)	9 Months Ended
	Sep. 30, 2015
Policies
New Accounting Pronouncements, Policy	In May 2014, new accounting guidance was issued that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. This guidance becomes effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. UTMD is currently assessing the impact that this standard will have on its consolidated financial statements when it is adopted in 2017.

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Details
Allocated Share-based Compensation Expense	$ 22	$ 25	$ 66	$ 49

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2015
Notes
Stock-Based Compensation	(4) Stock-Based Compensation. At September 30, 2015, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Stock Compensation. This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. In the quarters ended September 30, 2015 and 2014, the Company recognized $22 and $25, respectively, in stock-based compensation cost. In the nine months ended September 30, 2015 and 2014, the Company recognized $66 and $49, respectively, in stock based compensation cost.

Inventories: Schedule of Inventory, Current (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Details
Finished goods	$ 1,424	$ 1,847
Work-in-process	1,212	1,103
Raw materials	1,813	1,922
Total	$ 4,449	$ 4,872